CN1822812A - 使用n-酰基氨基酸组合物调节哺乳动物的角质组织 - Google Patents
使用n-酰基氨基酸组合物调节哺乳动物的角质组织 Download PDFInfo
- Publication number
- CN1822812A CN1822812A CNA2004800198619A CN200480019861A CN1822812A CN 1822812 A CN1822812 A CN 1822812A CN A2004800198619 A CNA2004800198619 A CN A2004800198619A CN 200480019861 A CN200480019861 A CN 200480019861A CN 1822812 A CN1822812 A CN 1822812A
- Authority
- CN
- China
- Prior art keywords
- skin care
- compositions
- skin
- acid
- care compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 259
- 230000033228 biological regulation Effects 0.000 title description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 23
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 17
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 7
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 alkanoyl hydroxyprolines Chemical class 0.000 claims description 120
- 239000000839 emulsion Substances 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000013543 active substance Substances 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 27
- 241001597008 Nomeidae Species 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 229930003270 Vitamin B Natural products 0.000 claims description 20
- 235000019156 vitamin B Nutrition 0.000 claims description 20
- 239000011720 vitamin B Substances 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 19
- 235000002378 plant sterols Nutrition 0.000 claims description 19
- 229960005190 phenylalanine Drugs 0.000 claims description 18
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 17
- 238000012545 processing Methods 0.000 claims description 16
- 230000000475 sunscreen effect Effects 0.000 claims description 15
- 239000000516 sunscreening agent Substances 0.000 claims description 15
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 14
- 239000002562 thickening agent Substances 0.000 claims description 13
- 206010040844 Skin exfoliation Diseases 0.000 claims description 11
- 230000035618 desquamation Effects 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 239000007854 depigmenting agent Substances 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 150000002215 flavonoids Chemical class 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 239000007762 w/o emulsion Substances 0.000 claims description 8
- 229940123457 Free radical scavenger Drugs 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 239000002516 radical scavenger Substances 0.000 claims description 7
- 230000037303 wrinkles Effects 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000013618 particulate matter Substances 0.000 claims description 6
- 230000003255 anti-acne Effects 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 208000035484 Cellulite Diseases 0.000 claims description 4
- 206010049752 Peau d'orange Diseases 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 6
- 235000000346 sugar Nutrition 0.000 abstract description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 abstract description 5
- 229960002591 hydroxyproline Drugs 0.000 abstract description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract description 5
- 150000001412 amines Chemical class 0.000 abstract description 4
- 229960003512 nicotinic acid Drugs 0.000 abstract description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
- 229930003537 Vitamin B3 Natural products 0.000 abstract 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 abstract 1
- 229960001915 hexamidine Drugs 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000011708 vitamin B3 Substances 0.000 abstract 1
- 235000019160 vitamin B3 Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 102
- 239000012071 phase Substances 0.000 description 50
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 44
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 44
- 239000004205 dimethyl polysiloxane Substances 0.000 description 42
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 41
- 229920001296 polysiloxane Polymers 0.000 description 38
- 239000003921 oil Substances 0.000 description 32
- 239000003995 emulsifying agent Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 24
- 229940008099 dimethicone Drugs 0.000 description 22
- 230000002265 prevention Effects 0.000 description 22
- 239000000049 pigment Substances 0.000 description 21
- 229920001971 elastomer Polymers 0.000 description 20
- 239000000806 elastomer Substances 0.000 description 20
- 230000000699 topical effect Effects 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 15
- 229920002379 silicone rubber Polymers 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 230000009286 beneficial effect Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- 239000004408 titanium dioxide Substances 0.000 description 12
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 11
- 239000003086 colorant Substances 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- 229920002545 silicone oil Polymers 0.000 description 10
- 125000005376 alkyl siloxane group Chemical group 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 229920006037 cross link polymer Polymers 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 8
- 230000001804 emulsifying effect Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 210000004905 finger nail Anatomy 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000000069 hyperpigmentation Diseases 0.000 description 7
- 230000003810 hyperpigmentation Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229930003799 tocopherol Natural products 0.000 description 7
- 229960001295 tocopherol Drugs 0.000 description 7
- 235000010384 tocopherol Nutrition 0.000 description 7
- 239000011732 tocopherol Substances 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 210000003298 dental enamel Anatomy 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000003349 gelling agent Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000346 nonvolatile oil Substances 0.000 description 6
- 229960003471 retinol Drugs 0.000 description 6
- 235000020944 retinol Nutrition 0.000 description 6
- 239000011607 retinol Substances 0.000 description 6
- 239000011787 zinc oxide Substances 0.000 description 6
- 235000014692 zinc oxide Nutrition 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229940048053 acrylate Drugs 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 5
- 150000004665 fatty acids Chemical group 0.000 description 5
- 150000002337 glycosamines Chemical class 0.000 description 5
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 5
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 5
- 235000008696 isoflavones Nutrition 0.000 description 5
- 210000000088 lip Anatomy 0.000 description 5
- 229950006780 n-acetylglucosamine Drugs 0.000 description 5
- 229920000058 polyacrylate Polymers 0.000 description 5
- 229920001451 polypropylene glycol Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 4
- 235000000431 campesterol Nutrition 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 4
- QDOXWKRWXJOMAK-UHFFFAOYSA-N dichromium trioxide Chemical compound O=[Cr]O[Cr]=O QDOXWKRWXJOMAK-UHFFFAOYSA-N 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 235000007173 Abies balsamea Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241001502050 Acis Species 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 241000239290 Araneae Species 0.000 description 3
- 239000004857 Balsam Substances 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- 239000011703 D-panthenol Substances 0.000 description 3
- 235000004866 D-panthenol Nutrition 0.000 description 3
- 235000002673 Dioscorea communis Nutrition 0.000 description 3
- 241000544230 Dioscorea communis Species 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 244000018716 Impatiens biflora Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- PMJRJYZRNYNQDP-UHFFFAOYSA-N N(=O)OC(C)CCCCCC.COC1=CC=C(C=CC(=O)O)C=C1 Chemical compound N(=O)OC(C)CCCCCC.COC1=CC=C(C=CC(=O)O)C=C1 PMJRJYZRNYNQDP-UHFFFAOYSA-N 0.000 description 3
- 208000035753 Periorbital contusion Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229960003949 dexpanthenol Drugs 0.000 description 3
- 229960000655 ensulizole Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 229940031674 laureth-7 Drugs 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 125000005375 organosiloxane group Chemical group 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- VUHMIPWBDMGTNL-MHCZMQLOSA-N 1,2-dimethoxy-4-[(e)-prop-1-enyl]benzene;1,2,4-trimethoxy-5-[(e)-prop-1-enyl]benzene Chemical compound COC1=CC=C(\C=C\C)C=C1OC.COC1=CC(OC)=C(\C=C\C)C=C1OC VUHMIPWBDMGTNL-MHCZMQLOSA-N 0.000 description 2
- HIPQTCQUXOFTFI-UHFFFAOYSA-N 2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)C(=O)C1=CC=CC=C1 HIPQTCQUXOFTFI-UHFFFAOYSA-N 0.000 description 2
- SGVYKUFIHHTIFL-UHFFFAOYSA-N 2-methylnonane Chemical compound CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- XHKWFVVYVGQSAI-QODDUVDKSA-N N[C@@H](CO)C(=O)O.N[C@@H](CCCCN)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.C(CCCCCCCCCCCCCCC)N[C@@H](CCCCN)C(=O)O Chemical compound N[C@@H](CO)C(=O)O.N[C@@H](CCCCN)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.C(CCCCCCCCCCCCCCC)N[C@@H](CCCCN)C(=O)O XHKWFVVYVGQSAI-QODDUVDKSA-N 0.000 description 2
- 235000019944 Olestra Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940085262 cetyl dimethicone Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004709 eyebrow Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000001023 inorganic pigment Substances 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012860 organic pigment Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229920002050 silicone resin Polymers 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 229960001296 zinc oxide Drugs 0.000 description 2
- 239000002888 zwitterionic surfactant Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- AKWSQGJVCCLJPB-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;3-aminopropanoic acid Chemical compound NCCC(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 AKWSQGJVCCLJPB-JEDNCBNOSA-N 0.000 description 1
- GYDYJUYZBRGMCC-INIZCTEOSA-N (2s)-2-amino-6-(dodecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCC(=O)NCCCC[C@H](N)C(O)=O GYDYJUYZBRGMCC-INIZCTEOSA-N 0.000 description 1
- PAEMERHSTIDLSE-VEIQOZLZSA-N (3r,4s,5s,6r)-2-hexadecoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PAEMERHSTIDLSE-VEIQOZLZSA-N 0.000 description 1
- RBOZTFPIXJBLPK-HWAYABPNSA-N (NE)-N-[(2E)-1,2-bis(furan-2-yl)-2-hydroxyiminoethylidene]hydroxylamine Chemical compound O\N=C(/C(=N\O)/C1=CC=CO1)\C1=CC=CO1 RBOZTFPIXJBLPK-HWAYABPNSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N 2,2,4,6,6-pentamethylheptane Chemical compound CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- TXYVFQZNQFQOFV-UHFFFAOYSA-N 2,2-dihydroxyethanesulfonic acid Chemical compound OC(O)CS(O)(=O)=O TXYVFQZNQFQOFV-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- MDMNSAVSQAHVLC-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 MDMNSAVSQAHVLC-MDTVQASCSA-N 0.000 description 1
- OBWBSSIUKXEALB-UHFFFAOYSA-N 2-aminoethanol;2-hydroxypropanamide Chemical compound NCCO.CC(O)C(N)=O OBWBSSIUKXEALB-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- ZCJRGONXXDDVLB-UHFFFAOYSA-N 28-Isofucosterolacetat Natural products CC=C(CCC(C)C1CCC2C3CCC4CC(CCC4(C)C3CCC12C)OC(=O)C)/C(C)C ZCJRGONXXDDVLB-UHFFFAOYSA-N 0.000 description 1
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical class C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 244000020998 Acacia farnesiana Species 0.000 description 1
- 235000003074 Acacia farnesiana Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical group CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004716 Ethylene/acrylic acid copolymer Substances 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CEAGUSGLAUVBEQ-UHFFFAOYSA-N Forosamine Natural products CC1CC(N(C)C)CC(O)O1 CEAGUSGLAUVBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 241001446187 Kermes Species 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920003347 Microthene® Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- BFWXAYQEKYNZQU-UHFFFAOYSA-N N(=O)OC(C)CCCCCC.OC1=C(C(=O)O)C=CC=C1 Chemical compound N(=O)OC(C)CCCCCC.OC1=C(C(=O)O)C=CC=C1 BFWXAYQEKYNZQU-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- FDSLJAYOPNMZIY-UXHICEINSA-N N-Hexadecyl-L-hydroxyproline Chemical class CCCCCCCCCCCCCCCCN1C[C@H](O)C[C@H]1C(O)=O FDSLJAYOPNMZIY-UXHICEINSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- CKFFCVRAFMDZTC-VOXJJDTJSA-N N[C@@H](CCCCN)C(=O)O.N[C@@H](CC1=CNC=N1)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O Chemical compound N[C@@H](CCCCN)C(=O)O.N[C@@H](CC1=CNC=N1)C(=O)O.C(CCCCCCCCCCCCCCC)NCC(=O)O CKFFCVRAFMDZTC-VOXJJDTJSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- OGTMPHGXBFNPSM-UHFFFAOYSA-N OC1=C2C(C(=COC2=CC(=C1)O)C1=CC=C(C=C1)O)=O.OC=1C(=C2C(C(=C(OC2=CC1)O)C1=CC=CC=C1)=O)O Chemical compound OC1=C2C(C(=COC2=CC(=C1)O)C1=CC=C(C=C1)O)=O.OC=1C(=C2C(C(=C(OC2=CC1)O)C1=CC=CC=C1)=O)O OGTMPHGXBFNPSM-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010037867 Rash macular Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical class [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- QAKVQPVSNCRRGJ-UHFFFAOYSA-N [I].C(CCC)NC(O)=O Chemical compound [I].C(CCC)NC(O)=O QAKVQPVSNCRRGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DHFCLYNGVLPKPK-UHFFFAOYSA-N acetamide;2-aminoethanol Chemical compound CC(N)=O.NCCO DHFCLYNGVLPKPK-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006208 butylation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LUNQZVCDZKODKF-PFVVTREHSA-L copper acetic acid (2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoate (2S)-6-amino-2-[[(2S)-2-[(2-amino-1-oxidoethylidene)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoate hydron Chemical compound [Cu+2].CC(O)=O.CC(O)=O.NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1.NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 LUNQZVCDZKODKF-PFVVTREHSA-L 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical group [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- FVCOIAYSJZGECG-UHFFFAOYSA-N diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 229920006228 ethylene acrylate copolymer Polymers 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 239000006081 fluorescent whitening agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- SZGAAHDUAFVZSS-SFYZADRCSA-N forosamine Chemical compound C[C@@H](O)[C@@H](N(C)C)CCC=O SZGAAHDUAFVZSS-SFYZADRCSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- OSELKOCHBMDKEJ-WGMIZEQOSA-N isofucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC/C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-WGMIZEQOSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229940081826 myristyl nicotinate Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 1
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- HOZMBDKPRFLCKN-UHFFFAOYSA-M potassium;2-[[9-(carboxymethylamino)-9-oxononanoyl]amino]acetate Chemical compound [K+].OC(=O)CNC(=O)CCCCCCCC(=O)NCC([O-])=O HOZMBDKPRFLCKN-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- ZXQVPEBHZMCRMC-UHFFFAOYSA-R tetraazanium;iron(2+);hexacyanide Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] ZXQVPEBHZMCRMC-UHFFFAOYSA-R 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TVGLGJWCZSCAEM-UHFFFAOYSA-N tetradecyl pyridine-3-carboxylate Chemical compound CCCCCCCCCCCCCCOC(=O)C1=CC=CN=C1 TVGLGJWCZSCAEM-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/45—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
护肤组合物,其包含:N-酰基氨基酸,尤其是苯基丙氨酸或酪氨酸的N-酰基衍生物、它们的异构体或它们的盐;至少一种其它护肤活性物质,所述其它护肤活性物质选自糖胺、维生素B3、类视色素、肽、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和植物甾醇;以及皮肤病学可接受的用于N-酰基氨基酸和护肤活性物质的载体。本发明还涉及调节哺乳动物的角质组织状况的不同方法,其中每个方法均包括将本发明安全有效量的护肤组合物局部施用到需要这种处理的哺乳动物角质组织上的步骤。
Description
技术领域
本发明涉及护肤组合物,所述护肤组合物包含N-酰基氨基酸、尤其是苯基丙氨酸或酪氨酸的N-酰基衍生物、它们的异构体或它们的盐与至少一种其它护肤活性物质的组合,所述其它护肤活性物质选自糖胺、维生素B3、类视色素、肽、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和植物甾醇。上述组合物可用于调节需要这种处理的哺乳动物角质组织状况。
发明背景
目前,有许多个人护理产品可供消费者采用,这些产品旨在改善角质组织(如皮肤、毛发和指甲)的健康和物理外观。这些产品大部分涉及延迟、最大程度地减少或甚至消除皮肤皱纹和其它组织学变化,所述组织学变化典型与皮肤老化或环境对人类皮肤的伤害有关。然而需要这样的美容剂,通过将其用作亮白或减轻色素沉着的美容剂可预防、延迟和/或处理不均匀的肤色。
哺乳动物的角质组织,尤其是人类皮肤,由于外部因素和内部因素而受到各种损伤。这种外部因素包括紫外线辐射、环境污染、风吹、日晒、红外线辐射、低湿度、刺激性的表面活性剂、研磨剂等等。另一方面,内部因素包括实足年龄和皮肤内的其它生化改变。无论是外部因素还是内部因素,这些因素都导致了可见的皮肤损伤迹象。典型的皮肤损伤包括皮肤减薄,当人上了年纪时其自然发生。随着这种减薄,供给皮肤的细胞和血管减少,真皮-表皮的连接也变平,这导致连接的机械阻力变弱。参见,例如,Oikarinen的“The Aging of Skin:ChronoagingVersus Photoaging,”Photodermatol.Photoimmunol.Photomed.,第7卷,第3至第4页,1990年。其它老化皮肤或受损皮肤上可见的损伤或改变包括细纹、褶皱、色素沉着过度、肤色灰黄、松垂、黑眼圈、肿眼、毛孔变大、更新速率降低以及异常的脱屑或脱皮。由于外部因素和内部因素而导致的更多的损伤包括可见的死皮(即剥落、脱皮、干燥、粗糙)。因此,需要有产品和方法来设法处理这些角质组织状况。
发明概述
不受理论的限制,已发现通过将某些包含N-酰基苯基丙氨酸或酪氨酸衍生物与附加护肤活性物质组合的组合物用作亮白或减轻色素沉着的美容剂,可预防、延迟和/或处理不均匀的肤色,其中所述附加护肤活性物质选自糖胺、维生素B3、类视色素、肽、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和植物甾醇。
因此,申请者已惊奇地发现,包含特效N-酰基苯基丙氨酸或N-酰基酪氨酸或它们衍生物与至少一种其它护肤活性物质组合的局部组合物,可用于向角质组织状况提供预防性以及治疗性处理,其中所述其它护肤活性物质选自糖胺、维生素B3、类视色素、肽、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和植物甾醇。例如,申请者已发现,通过将上述组合物用作亮白或减轻色素沉着的美容剂,可用于预防、延迟和/或处理不均匀的肤色;预防、延迟和/或处理黑眼圈、肿眼、松垂、肤色灰黄以及蛛形血管和/或皮肤红斑,促进皮肤脱屑、脱皮和/或更新,调节和/或减少毛孔大小外观,预防/延迟晒黑,调节油性/光泽的外观,预防、延迟和/或处理哺乳动物皮肤中的色素沉着过度(如发炎后色素沉着过度、色斑如老年斑等),预防、延迟和/或处理哺乳动物皮肤上的瘙痒,预防、延迟和/或处理皮肤干燥,预防、延迟和/或处理细纹和皱纹,预防、延迟和/或处理哺乳动物的皮肤萎缩,和/或软化和/或平滑哺乳动物的嘴唇、毛发和指甲。
本发明涉及护肤组合物,所述组合物包含:
a)安全有效量的N-酰基氨基酸,所述N-酰基氨基酸选自N-酰基苯基丙氨酸、N-酰基酪氨酸、它们的异构体、它们的盐、以及它们的衍生物;
b)安全有效量的至少一种护肤活性物质,所述护肤活性物质选自糖胺、维生素B3、类视色素、肽、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和植物甾醇、它们的衍生物以及它们的组合;和
c)皮肤病学可接受的载体,所述载体用于N-酰基氨基酸和护肤活性物质。
本发明还涉及调节哺乳动物的角质组织状况的不同方法,其中每个方法均包括将本发明安全有效量的护肤组合物局部施用到需要这种处理的哺乳动物角质组织上的步骤。
发明详述
除非另外指明,本文中使用的所有百分比和比率均以总组合物的重量计,并且所有的测量均在25℃进行。
本发明的组合物可包含、基本上由或由本文所描述的基本组分以及非必需成分组成。本文所用的“基本上由...组成”是指所述组合物或组分可包括附加成分,只要所述附加成分不会在本质上改变本发明要求保护的组合物或方法的基本和新的特性。
本文所用术语“角质组织”是指作为哺乳动物最外层保护覆盖物的含角质层,其包括但不限于皮肤、毛发、脚趾甲、手指甲、表皮、蹄等。
本文所用术语“局部应用”是指将本发明的组合物施用或涂抹到角质组织表面上。
本文所用术语“皮肤病学可接受的”是指所述组合物或组分适用于与人类的角质组织接触,而没有不适当的毒性、不相容性、不稳定性、变应性反应等。
本文所用术语“安全有效量”是指在技术人员合理的判断范围内,化合物或组合物的量足以显著产生积极的有益效果,优选积极的角质组织外观或感觉有益效果,该有益效果包括本文所公开的独立的或组合的有益效果,但该量又足够低以避免严重的副作用,即提供合理的效险比。
本文所用术语“发炎后色素沉着过度”是指发炎事件(如粉刺、擦伤、昆虫刺伤、日晒红斑等)所反应出的黑色素含量的变化,尤其是黑色皮肤个体。
本文所用术语“色素沉着过度”是指色素沉着大于邻近皮肤区域的皮肤区域(如色斑、老年斑等)。
本文所用术语“脱屑、脱皮和/或更新”是指角质层上层(包括角质层)的去除。
本文所用术语“油性和/或光泽外观”是指具有光滑外观的哺乳动物皮肤趋于显示出从各自的腺体分泌的油脂、皮脂和/或汗液。
本文所用术语“松垂”是指由于皮肤弹性蛋白的损失、损坏、改变和/或畸形而导致的皮肤松弛、松懈等等状况。
本文所用术语“光滑”和“软化”是指改变角质组织的表面以改进触感。
本文所用术语“肤色灰黄”是指由于诸如蛋白质糖化作用和脂褐素积累的过程或典型地伴随着皮肤老化的周边血流量的减少,皮肤组分损失、损坏、改变和/或畸形以至它们变色(如黄色)而导致的肤色呈灰白、黄色等等状况。
本发明组合物在局部应用和调节角质组织状况方面有用。由于机体的内在因素和/或外在因素常可诱发或导致各种症状,所以经常需要对角质组织状况、尤其是人类的皮肤状况进行调节。例如,“调节皮肤状况”包括预防性调节和/或治疗性调节皮肤状况,并且可包括下列一种或多种有益效果:增厚(即构造皮肤的表皮和/或真皮层,和/或皮下层如脂肪层和肌肉层,且这里可适用于指甲和发干的角质层)以减少萎缩(如皮肤的萎缩),增加真皮-表皮边界的卷积,非黑色素皮肤褪色如眼袋、疤斑(例如,如红斑痤疮引起的不均匀的红色)(以下称作为红斑)、肤色灰黄(灰白色或黄色),由毛细管扩张或蛛形血管引起的褪色,由黑色素(如色斑、老年斑、不均匀色素沉着)和皮肤中其它发色团(例如脂褐素、蛋白质交联如随糖化作用出现的那些,等等)引起的褪色。本文所用的预防性调节皮肤状况包括延迟、最大程度地减少和/或预防可见的和/或可触及的皮肤不连续性(例如,不规则的纹理、细纹、皱纹、松垂、拉伸痕迹、蜂窝炎、肿眼等等皮肤中可看到的或感觉到的)。本文所用的处理性调节皮肤状况包括改善皮肤的不连续性(例如减少、最小化和/或消除皮肤的不连续性。调节皮肤状况包括改善皮肤外观和/或感觉。)
本文所用术语“调节皮肤状况”将包括这些迹象的调节而不管成因的机理。
包括基本组分及其非必需组分的本发明的组合物将在下文详述。
组分
N-酰基氨基酸化合物
本发明的局部组合物包含安全有效量的一种或多种N-酰基氨基酸化合物。所述氨基酸可以是本领域已知的任何一种氨基酸。本发明的N-酰基氨基酸化合物符合下式结构:
其中R可以是氢、烷基(取代或未取代的、支链或直链的)、或烷基和芳基的组合。本领域已知氨基酸的可能侧链列表描述于Stryer的“Biochemistry”(1981)中,其由W.H.Freeman and Company公布。R1可以是C1至C30的饱和或不饱和的、直链或支链的、取代或未取代的烷基,取代或未取代的芳基、或它们的混合物。
N-酰基氨基酸化合物优选选自N-酰基苯基丙氨酸、N-酰基酪氨酸、它们的异构体、它们的盐、以及它们的衍生物。氨基酸可以是D或L异构体、或它们的混合物。N-酰基苯基丙氨酸符合下式结构:
其中R1可以是C1至C30的饱和或不饱和的、直链或支链的、取代或未取代的烷基,取代或未取代的芳基、或它们的混合物。
N-酰基酪氨酸符合下式结构:
其中R1可以是C1至C30的饱和或不饱和的、直链或支链的、取代或未取代的烷基,取代或未取代的芳基、或它们的混合物。
尤其可用作局部肤色匀化(亮白或减轻色素沉着)美容剂的是N-十一碳烯酰基-L-苯基丙氨酸。此试剂属于广义的N-酰基苯基丙氨酸衍生物,其酰基为C11单不饱和脂肪酸部分,并且氨基酸为苯基丙氨酸的L-异构体。N-十一碳烯酰基-L-苯基丙氨酸符合下式结构:
本文所用的N-十一碳烯酰基-L-苯基丙氨酸可以商品名Sepiwhite市购自SEPPIC。
在本发明组合物中,N-酰基氨基酸的含量按所述组合物的重量计优选为约0.0001%至25%,更优选约0.001%至10%,更优选约0.01%至5%,甚至更优选约0.02%至2.5%。
护肤活性物质
本发明包含护肤活性物质,其选自糖胺、维生素B3、类视色素、肽、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和植物甾醇、它们的衍生物以及它们的组合。
1.
糖胺(氨基糖)
本发明的组合物非必需地包括安全有效量的糖胺,其也被称为氨基糖。可用于本发明中的糖胺化合物描述于PCT公布WO 02/076423和美国专利6,159,485中。
该组合物优选包含按所述组合物的重量计约0.01%至约15%,更优选约0.1%至约10%,甚至更优选约0.5%至约5%的糖胺。
糖胺来源于合成或自然,且可作为纯化合物或化合物的混合物(例如源自天然的提取物或合成物质的混合物)来使用。葡糖胺通常存在于许多甲壳类动物中,并且也可衍生自真菌源。本文所用术语“糖胺”包括上述物质及其盐(如HCl盐)的异构体和互变异构体,且市售于Sigma Chemical Co.。
可用于本发明的糖胺的实施例包括葡糖胺、N-乙酰氨基葡糖、甘露糖胺、N-乙酰甘露糖胺、半乳糖胺、N-乙酰半乳糖胺、它们的异构体(如立体异构体)和它们的盐(如HCl盐)。优选可用于本文的是葡糖胺,尤其是D-葡糖胺和N-乙酰氨基葡糖,尤其是N-乙酰基-D-葡糖胺。
2.维生素B3
本发明组合物可包含安全有效量的维生素B3化合物。维生素B3化合物尤其可用于调节皮肤状况,如美国专利5,939,082中所述。该组合物包含按所述组合物的重量计约0.01%至约50%,更优选约0.1%至约20%,甚至更优选约0.5%至约10%,还更优选约1%至约7%,甚至更优选约2%至约5%的维生素B3化合物。
本文所用的“维生素B3化合物”是指具有下式结构的化合物:
其中R是-CONH2(即烟酰胺)、-COOH(即烟酸)或-CH2OH(即烟醇),它们的衍生物,和任意前述化合物的盐。
前述维生素B3化合物的示例性衍生物包括烟酸酯,所述酯包括烟酸的非血管舒张性酯(如生育酚烟酸酯、十四烷基烟酸酯)。
适宜维生素B3化合物的实施例是本领域熟知的,并且可市售自多个来源(如Sigma Chemical Company,ICN Biomedicals,Inc.,和Aldrich Chemical Company)。
3.
类视色素
本发明组合物可包含安全有效量的类视色素,以使所得组合物可安全有效地用于调节角质组织状况,优选用于调节看得见的和/或能触及的皮肤不连续性,更优选用于调节皮肤老化体症。该组合物优选包含按所述组合物的重量计约0.001%至约10%,更优选约0.005%至约2%,甚至更优选约0.01%至约1%,还更优选约0.01%至约0.5%的类视色素。组合物中所用的最佳浓度将取决于所选择的具体类视色素,因为它们的效力具有相当大的不同。
本文中使用的“类视色素”包括对于皮肤具有维生素A生物活性的所有天然和/或合成的维生素A类似物或类似视黄醇的化合物,以及这些化合物的几何异构体和立体异构体。类视色素优选选自视黄醇、视黄醇酯(例如视黄醇的C2-C22烷基酯,包括棕榈酸视黄酯、乙酸视黄酯、丙酸视黄酯)、视黄醛和/或视黄酸(包括全反式视黄酸和/或13-顺式视黄酸)或它们的混合物。更优选类视色素是除视黄酸之外的类视色素。优选的类视色素有视黄醇、棕榈酸视黄酯、乙酸视黄酯、丙酸视黄酯、视黄醛以及它们的组合。更优选丙酸视黄酯,其用量甚至更优选为约0.1%至约0.3%。
4.
肽
本发明组合物可包含安全有效量的肽,包括,但不限于二-、三-、四-、五-和六-肽及其衍生物。该组合物包含按所述组合物的重量计优选约1×10-6%至约20%,更优选约1×10-6%至约10%,甚至更优选约1×10-5%至约5%的肽。
本文所用术语“肽”是指包含十个或较少氨基酸的肽和它们的衍生物、异构体,以及与其它种类如金属离子(如铜、锌、锰、镁等等)的配合物。本文所用的肽既指天然存在的肽又指合成的肽。还可用于本文的是天然存在的和市售的含肽组合物。更优选的肽是二肽肌肽(β-丙氨酸-组氨酸)、三肽甘氨酸-组氨酸-赖氨酸、五肽赖氨酸-苏氨酸-苏氨酸-赖氨酸-丝氨酸、肽的亲脂性衍生物,以及上述的金属配合物,如三肽组氨酸-甘氨酸-甘氨酸(也称为Iamin)的铜配合物。优选包含三肽衍生物的市售组合物是Biopeptide CL,其包含100ppm的棕榈酰-甘氨酸-组氨酸-赖氨酸,且市售于Sederma。优选包含五肽衍生物的市售组合物是Matrixyl,其包含100ppm的棕榈酰-赖氨酸-苏氨酸-苏氨酸-赖氨酸-丝氨酸,且市售于Sederma。
5.
植物甾醇
本发明的局部组合物包含安全有效量的一种或多种植物甾醇,其选自β-谷甾醇、菜油甾醇、芸苔甾醇、Δ5-燕麦甾醇、羽扇豆醇、α-菠菜甾醇、豆甾醇、它们的衍生物、类似物以及它们的组合。更优选地,植物甾醇选自β-谷甾醇、菜油甾醇、芸苔甾醇、豆甾醇、它们的衍生物、以及它们的组合。更优选地,植物甾醇是豆甾醇。
植物甾醇来源于合成或自然,且可作为纯化合物或化合物的混合物(例如源自天然的提取物)来使用。植物甾醇通常存在于植物油和脂肪的未皂化部分中,它们以游离甾醇、乙酰化衍生物、甾醇酯、乙氧基化或葡糖苷衍生物的形式获得。更优选地,植物甾醇是游离甾醇。本文所用术语“植物甾醇”包括上述物质的异构体和互变异构体,并且市售于Aldrich Chemical Company,Sigma Chemical Company和Cognis。
在本发明组合物中,植物甾醇的含量优选为所述组合物重量的约0.0001%至约25%,更优选约0.001%至约15%,甚至更优选约0.01%至约10%,还更优选约0.1%至约5%,甚至更优选约0.2%至约2%。
6.
去氧苯比妥
可用于本发明的去氧苯比妥化合物符合下列那些化学结构:
其中R1和R2包括有机酸(如磺酸等)。
在本发明的组合物中,去氧苯比妥的含量优选为所述组合物重量的约0.0001%至约25%,更优选约0.001%至约10%,更优选约0.01%至约5%,甚至更优选约0.02%至约2.5%。
本发明的局部组合物非必需地包含安全有效量的一种或多种去氧苯比妥化合物及其盐和衍生物。本文所用的“去氧苯比妥衍生物”包括去氧苯比妥化合物的所有异构体和互变异构体,包括但不限于有机酸和无机酸,例如磺酸、羧酸等。优选地,去氧苯比妥化合物包括二羟乙基磺酸去氧苯比妥,其以商品名ElestabHP100市售于LaboratoiresSerobiologiques。
7.
二烷酰基羟脯氨酸化合物
本发明的二烷酰基羟脯氨酸化合物符合下列那些化学结构:
其中R1包括H、X、C1-C20直链或支链烷基,
X包括金属(Na、K、Li、Mg、Ca)或胺(DEA、TEA);
R2包括C1-C20直链或支链烷基;
R3包括C1-C20直链或支链烷基。
本发明的局部组合物可包含安全有效量的一种或多种二烷酰基羟脯氨酸化合物及其盐和衍生物。在本发明的组合物中,二烷酰基羟脯氨酸化合物的含量优选为所述组合物重量的约0.01%至10%,更优选约0.1%至5%,甚至更优选约0.1%至2%。
适宜的衍生物包括但不限于酯如脂肪族酯,包括但不限于,三棕榈酰羟脯氨酸和二棕榈基乙酰基羟脯氨酸。尤其可用的化合物是二棕榈酰羟脯氨酸。本文所用的二棕榈酰羟脯氨酸包括上述物质的所有异构体和互变异构体,并且以商品名Sepilift DPHP市售于Seppic,Inc.。二棕榈酰羟脯氨酸的进一步论述可见于PCT公布WO 93/23028中。二棕榈酰羟脯氨酸优选为二棕榈酰羟脯氨酸的三乙醇胺盐。
8.
水杨酸化合物
本发明的局部组合物可包含安全有效量的水杨酸化合物、它的酯、它的盐、或它们的组合。在本发明组合物中,水杨酸化合物的含量优选为所述组合物重量的约0.0001%至约25%,更优选约0.001%至约15%,甚至更优选约0.01%至约10%,还更优选约0.1%至约5%,甚至更优选约0.2%至约2%。
皮肤病学可接受的载体
本发明的局部组合物还包含用于N-酰基氨基酸组合物的皮肤病学可接受的载体。本文所用短语“皮肤病学可接受的载体”是指载体适合局部应用于角质组织,具有良好的美学性质,与本发明的活性物质以及任何其它组分相容,并且不引起任何安全或毒性问题。载体的安全有效量为所述组合物重量的约50%至约99.99%,优选约60%至约99.9%,更优选约70%至约98%,甚至更优选约80%至约95%。
载体可呈多种形式。例如,乳液载体可用于本发明,所述乳液载体包括,但不限于水包油、油包水、水包油包水和硅氧烷包水包油乳液。
优选的载体包含乳液(如水包油乳液和油包水乳液),例如水包硅氧烷乳液或硅氧烷包水乳液。正如技术人员所理解的那样,给定组分应主要分配到水或油相中,这取决于该组分在组合物中的水溶性/可分配性。尤其优选水包油乳液。
本发明乳液一般包含如上所述的溶液和类脂或油。类脂和油可得自动物、植物或石油,并且可以是天然或合成的(即人工制得的)。优选的乳液还包含湿润剂,例如甘油。乳液优选还包含按所述组合物的重量计约0.1%至约10%,更优选约0.2%至约5%的乳化剂。乳化剂可以是非离子、阴离子或阳离子的。适宜的乳化剂公开于,例如,美国专利3,755,560、美国专利4,421,769和McCutcheon的“Detergents andEmulsifiers”北美版第317页至第324页(1986年)中。
根据所需的产品类型,合适的乳液可具有范围很宽的粘度。优选的示例性低粘度乳液的粘度为约50厘沲或更低,更优选约10厘沲或更低,甚至更优选约5厘沲或更低。
下面更详细地描述优选的油包水和水包油乳液。
1.
油包水乳液
油包水乳液的特征在于其具有连续的疏水的水不溶性油相和分散在其中的水相。“油相”可包含油、硅氧烷或它们的混合物。乳液表征为油包水乳液还是硅氧烷包水乳液的区别,取决于油相主要是由油还是由硅氧烷组成。下面描述一个硅氧烷包水乳液的优选实施例。
a.
连续硅氧烷相
本发明优选的硅氧烷包水乳液包含按重量计约1%至约60%,优选约5%至约40%,更优选约10%至约30%的连续硅氧烷相。连续硅氧烷相作为外相存在,其包含或环绕着在下文中描述的不连续水相。
连续硅氧烷相包含硅氧烷弹性体和/或聚有机硅氧烷油。这些优选乳液的连续硅氧烷相包含按重量计约50%至约99.9%的有机聚硅氧烷油和按重量计低于约50%的非硅氧烷油。在优选的实施方案中,连续硅氧烷相包含按所述连续硅氧烷相的重量计至少约50%,优选约60%至约99.9%,更优选约70%至约99.9%,甚至更优选约80%至约99.9%的聚有机硅氧烷油,和最高约50%,优选低于约40%,更优选低于约30%,甚至更优选低于约10%,还更优选低于约2%的非硅氧烷油。
b.
聚有机聚硅氧烷油
用于所述组合物中的有机聚硅氧烷油可以是挥发性的、非挥发性的、或挥发性与非挥发性硅氧烷的混合物。在本文中使用的术语“非挥发性”是指在环境条件下为液体、并且闪点(在一个大气压下)为约100℃或更高的那些硅氧烷。在本文中使用的术语“挥发性”是指所有其它硅氧烷油。合适的有机聚硅氧烷可选自挥发性和粘度跨度很大的多种硅氧烷。合适的有机硅氧烷油的实施例包括聚烷基硅氧烷、环聚烷基硅氧烷和聚烷基芳基硅氧烷。
可用于本文组合物中的聚烷基硅氧烷包括25℃下粘度为约5×10-7至约1m2/s(约0.5至约1,000,000厘沲)的聚烷基硅氧烷。市售的聚烷基硅氧烷包括聚二甲基硅氧烷,其还被称为聚二甲基硅氧烷,它的实施例包括售自General Electric Company的Vicasil系列和售自Dow Corning Corporation的Dow Corning200系列。适用于组合物中的环状聚烷基硅氧烷包括市售的那些,如Dow Corning244,Dow Corning344流体,和Dow Corning345流体。
还可用的物质如三甲基甲硅烷氧基硅酸酯,它是符合化学通式[(CH2)3SiO1/2]x[SiO2]y的聚合材料,其中x是约1至约500的整数,且y是约1至约500的整数。市售的三甲基甲硅烷氧基硅酸酯是带有聚二甲基硅氧烷的混合物,以商品名Dow Corning593流体出售。
聚二甲基硅氧烷醇也适用于该组合物。这些化合物可以化学式R3SiO[R2SiO]xSiR2OH和HOR2SiO[R2SiO]xSiR2OH表示,其中R是烷基(R优选为甲基或乙基,更优选为甲基),并且x是0至约500的整数,选择x以达到所需的分子量。市售的聚二甲基硅氧烷醇典型地以含聚二甲基硅氧烷或环状聚甲基硅氧烷的混合物(例如Dow Corning1401、1402和1403流体)出售。
聚烷基芳基硅氧烷也适用于该组合物。25℃下粘度为约1.5×10-5至约6.5×10-5(约15至约65厘沲)的聚甲基苯基硅氧烷是尤其有用的。
优选用于本发明的是选自下列物质的有机硅氧烷:聚烷基硅氧烷、烷基取代的聚二甲基硅氧烷、环状聚甲基硅氧烷、三甲基甲硅烷氧基硅酸酯、聚二甲基硅氧烷醇、聚烷基芳基硅氧烷以及它们的混合物。更优选用于本发明的是聚烷基硅氧烷和环状聚甲基硅氧烷。在聚烷基硅氧烷当中,聚二甲基硅氧烷是优选的。
如上所述,连续硅氧烷相可能包含一种或多种非硅氧烷油。合适的非硅氧烷油的熔点在约一个大气压下为约25℃或更低。适用于连续硅氧烷相的非硅氧烷油的实施例是化学领域熟知的以油包水乳液形式的局部个人护理产品的那些,例如矿物油、植物油、合成油、半合成油等。
c.
硅氧烷弹性体
本发明的组合物还包含按所述组合物的重量计约0.1%至约30%的硅氧烷弹性体组分。该组合物优选包含按所述组合物的重量计约1%至约30%,更优选约2%至约20%的硅氧烷弹性体组分。
适用于本发明的硅氧烷弹性体可以是乳化的或未乳化的交联硅氧烷弹性体或其混合物。对于可固化的有机硅氧烷组合物类型不存在特别的限制,其可用作交联化有机硅氧烷弹性体的原料。此方面的实施例是加成反应固化有机聚硅氧烷组合物,该组合物在金属铂催化作用下,通过含SiH的二有机基聚硅氧烷和具有与硅键合乙烯基的有机聚硅氧烷之间的加成反应进行固化;缩合固化有机聚硅氧烷组合物,该组合物在有机锡化合物的存在下,通过在羟基封端的二有机基聚硅氧烷和含SiH的二有机基聚硅氧烷之间发生脱氢发应进行固化;和缩合固化有机聚硅氧烷组合物,该组合物在有机锡化合物或钛酸酯的存在下进行固化。
优选加成反应固化的有机聚硅氧烷组合物,因为其固化速率快且有极好的固化均匀性。尤其优选加成反应固化的有机聚硅氧烷组合物,其按以下方法制备:
(A)在每一分子中具有至少2个低级链烯基的有机聚硅氧烷;
(B)在每一分子中具有至少2个与硅键合的氢原子的有机聚硅氧烷;和
(C)一种铂型的催化剂。
本发明的组合物可包含乳化交联的有机聚硅氧烷弹性体、非乳化交联的有机聚硅氧烷弹性体或它们的混合物。本文所用术语“非乳化”用于定义不含聚氧化烯单元的交联有机聚硅氧烷弹性体。本文所用术语“乳化”是指具有至少一个聚氧化烯(例如聚氧乙烯或聚氧丙烯)单元的交联有机聚硅氧烷弹性体。本文优选的乳化弹性体包括聚氧化烯改性的弹性体,其是由二乙烯基化合物,尤其是具有至少两个游离乙烯基的硅氧烷聚合物,在聚硅氧烷主链上与Si-H键反应而形成的。优选地,所述弹性体为分子球形MQ树脂上通过Si-H位点交联形成的二甲基聚硅氧烷。乳化的交联有机聚硅氧烷弹性体可特别地选自美国专利5,412,004、5,837,793和5,811,487中所描述的交联聚合物。此外,由聚二甲基硅氧烷共聚多元醇交联聚合物(和)聚二甲基硅氧烷组成的乳化弹性体可以商品名KSG-21购自Shin Etsu。
优选地,该非乳化弹性体是聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物。这类聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物可由很多供应商供应,包括Dow Corning(DC 9040和DC 9041),General Electric(SFE 839),Shin Etsu(KSG-15、16、18[聚二甲基硅氧烷/苯基乙烯基聚二甲基硅氧烷交联聚合物])和GrantIndustries(GRANSILTM系列弹性体)。可用于本发明的交联有机聚硅氧烷弹性体及其制备方法进一步描述于美国专利4,970,252、美国专利5,760,116和美国专利5,654,362中。其它可用于本发明的交联有机聚硅氧烷弹性体公开于转让给Pola Kasei Kogyo KK的日本专利申请JP 61-18708中。
优选用于本文的市售弹性体为Dow Corning的9040硅氧烷弹性体共混物、Shin Etsu的KSG-21以及它们的混合物。
d.
用于硅氧烷弹性体的载体
本发明的局部组合物包含按所述组合物的重量计约1%至约80%的用于上文所述交联有机聚硅氧烷弹性体组分的适宜载体。当该载体与本发明的交联有机聚硅氧烷弹性体颗粒相结合后,可用于悬浮和溶胀该弹性体颗粒,以提供弹性胶状网络或基质。用于交联硅氧烷弹性体的载体在环境条件下是液体并且优选具有低的粘度,以提供改进的在皮肤上的扩散。
本发明化妆品组合物中,载体的浓度将主要随载体的类型和用量以及所用的交联硅氧烷弹性体而变化。载体的浓度按所述组合物的重量计优选为约5%至约50%,更优选约5%至约40%。
用于交联硅氧烷弹性体的载体包括一种或多种适宜局部施用于人体皮肤的液体载体。这些液体载体可以是有机的、包含硅氧烷的或包含氟的、挥发性的或非挥发性的、极性的或非极性的,前提条件是该液体载体可在选定的硅氧烷弹性体浓度下与选定的交联硅氧烷弹性体在为约28℃至约250℃,优选约28℃至约100℃,优选约28℃至约78℃的温度下,形成溶液或其它均一化液体或液体分散体。本发明所使用的术语“挥发性的”是指所有那些不是由本发明先前定义的“非挥发性的”物质。本发明所使用的短语“相对极性”是指在溶解度参数方面比其它物质极性更大,即溶解度参数越高,液体极性就越大。术语“非极性”典型地是指物质具有的溶解度参数低于约6.5(cal/cm3)0.5。
e.
非极性挥发性油
该非极性挥发性油倾向赋予本发明组合物高度所需的美学特征。因此,该非极性挥发性油优选地以相当高的含量被使用。尤其可用于本发明中的非极性挥发性油是硅油、烃以及它们的混合物。上述非极性挥发性油公开于,例如,Balsam和Sagarin编辑的“Cosmetics,Science,and Technology”第1卷第27页至第104页(1972年)中。优选的非极性挥发性烃的实施例包括polydecanes如异十二烷和异癸烷(如购自Presperse Inc.的Permethyl-99A)和C7-C8至C12-C15异链烷烃(如购自Exxon Chemicals的Isopar系列)。尤其优选的挥发性硅油选自符合下式的环状挥发性硅氧烷:
其中n为约3至约7;和符合下式的直链挥发性硅氧烷:
(CH3)3Si--O--[Si(CH3)2-O]m--Si(CH3)3
其中m为约1至约7。直链挥发性的硅氧烷在25℃下通常具有小于约5厘沲的粘度,但是该环状硅氧烷在25℃下具有小于约10厘沲的粘度。高度优选的挥发性硅油的实施例包括不同粘度的环状聚甲基硅氧烷,例如Dow Corning 200、Dow Corning 244、Dow Corning 245、Dow Corning 344和Dow Corning 345(购自Dow Corning Corp.);SF-1204和SF-1202聚硅氧烷流体(购自G.E.Silicones),GE 7207和7158(购自General Electric Co.)和SWS-03314(购自SWSSilicones Corp.)。
f.
相对极性非挥发性油
该非挥发性油与上述非极性挥发性油相比较是“相对极性的”。因此,该非挥发性共载体比至少一种非极性挥发性油极性更大(即,具有更高的溶解度参数)。可潜在用于本发明的相对极性非挥发性油公开于,例如,Balsam和Sagarin编辑的“Cosmetics,Science,andTechnology”第1卷第27页至第104页(1972年)、美国专利4,202,879和4,816,261中。可用于本发明中的相对极性非挥发性油优选选自硅油、烃油、脂肪醇、脂肪酸、一元和二元羧酸与一元和多元醇的酯、聚氧乙烯、聚氧丙烯、脂肪醇聚氧乙烯醚和脂肪醇聚氧丙烯醚的混合物以及它们的混合物。
g.
非极性非挥发性油
除了上述液体以外,用于交联硅氧烷弹性体的载体还可非必需地包括非挥发性非极性油。典型的非挥发性非极性的润肤剂公开于,例如,Balsam和Sagarin编辑的“Cosmetics,Science,and Technology”第1卷第27页至第104页(1972年)、美国专利4,202,879和4,816,261中。可用于本发明的非挥发性的油基本上是非挥发性的聚硅氧烷、石蜡烃油以及它们的混合物。
h.
水分散相
本发明的局部组合物包含约30%至约90%,更优选约50%至约85%,甚至更优选约70%至约80%的水分散相。在乳液技术中,术语“分散相”是本领域技术人员熟知的术语,其是指该相作为悬浮在连续相中并被连续相包围的小颗粒或小滴存在。分散相还称为内相或不连续相。水分散相是悬浮在上述连续硅氧烷相中并被连续硅氧烷相包围的含水小颗粒或小液滴的分散体。
水相可以是水,或者是水与一种或多种水溶性或水可分散性组分的混合物。这样的非必需组分的非限制性实施例包括增稠剂、酸、碱、盐、螯合剂、胶、水溶性或水可分散性醇和多元醇、缓冲剂、防腐剂、防晒剂、着色剂等。
在水分散相中,本发明的局部组合物可典型地包含按所述组合物的重量计约25%至约90%,优选约40%至约85%,更优选约60%至约80%的水。
i.
用于水分散相的乳化剂
本发明的硅氧烷包水乳液优选地包含乳化剂。在优选的实施方案中,该组合物包含按所述组合物的重量计约0.1%至约10%,更优选约0.2%至约7.5%,甚至更优选约0.5%至约5%的乳化剂。乳化剂有助于将水相分散并悬浮在连续硅氧烷相中。
很多种乳化剂都可用于本发明中以形成优选的硅氧烷包水乳液。已知的或传统的乳化剂可用于该组合物中,前提条件是所选择的乳化剂在化学上和物理上与组合物的基本组分相容,且能提供所需的分散特性。合适的乳化剂包括硅氧烷乳化剂、不含硅氧烷的乳化剂以及它们的混合物,这些用于局部个人护理产品中的乳化剂为本领域的技术人员所熟知。这些乳化剂的HLB值优选小于约14,更优选约2至约14,甚至更优选约4至约14。HLB值不在这些范围内的乳化剂可以与其它乳化剂联合使用以使该组合的有效重均HLB落在这些范围内。
优选硅氧烷乳化剂。有很多种硅氧烷乳化剂可用于本发明。这些硅氧烷乳化剂典型地是作为硅氧烷表面活性剂并且为本领域技术人员所知的有机改性的有机聚硅氧烷。有用的硅氧烷乳化剂包括聚二甲基硅氧烷共聚多元醇。
可用作本文乳化剂的聚二甲基硅氧烷共聚多元醇和其它硅氧烷表面活性剂的非限制性实施例包括:具有聚氧化乙烯侧链的聚二甲基硅氧烷聚醚共聚物,具有聚氧化丙烯侧链的聚二甲基硅氧烷聚醚共聚物,具有混合的聚氧化乙烯和聚氧化丙烯侧链的聚二甲基硅氧烷聚醚共聚物,具有混合聚氧化(乙烯)(丙烯)侧链的聚二甲基硅氧烷聚醚共聚物,具有有机甜菜碱侧链的聚二甲基硅氧烷聚醚共聚物,具有羧酸盐侧链的聚二甲基硅氧烷聚醚共聚物,具有季铵侧链的聚二甲基硅氧烷聚醚共聚物,以及含有C2-C30直链、支链或环状烷基侧链部分的上述共聚物的进一步改性物。可用于本发明的由Dow Corning公司销售的市售聚二甲基硅氧烷共聚多元醇的实施例有Dow Corning190、193、Q2-5220、2501 Wax、2-5324流体和3225C(后者作为与环状聚甲基硅氧烷的混合物销售)。鲸蜡基聚二甲基硅氧烷共聚多元醇是作为与聚甘油基-4异硬脂酸酯(和)月桂酸己酯的混合物商购获得,并且以商品名ABILWE-09销售(得自Goldschmidt)。鲸蜡基聚二甲基硅氧烷共聚多元醇还作为与月桂酸己酯(和)聚甘油基-3油酸酯(和)鲸蜡基聚二甲基硅氧烷的混合物商购获得,并且以商品名ABILLWS-08销售(也得自Goldschmidt)。聚二甲基硅氧烷共聚多元醇的其它非限制性实施例还包括月桂基聚二甲基硅氧烷共聚多元醇、聚二甲基硅氧烷共聚多元醇乙酸酯、聚二甲基硅氧烷共聚多元醇己二酸酯、聚二甲基硅氧烷共聚多元醇胺、聚二甲基硅氧烷共聚多元醇二十二烷酸酯、聚二甲基硅氧烷共聚多元醇丁基醚、聚二甲基硅氧烷共聚多元醇羟基硬脂酸酯、聚二甲基硅氧烷共聚多元醇异硬脂酸酯、聚二甲基硅氧烷共聚多元醇月桂酸酯、聚二甲基硅氧烷共聚多元醇甲基醚、聚二甲基硅氧烷共聚多元醇磷酸酯和聚二甲基硅氧烷共聚多元醇硬脂酸酯。
在不含硅氧烷的乳化剂中,可用于本发明的有各种不同的非离子和阴离子乳化剂例如糖酯和聚酯、烷氧化糖酯和聚酯、C1-C30脂肪醇的C1-C30脂肪酸酯、C1-C30脂肪醇的C1-C30脂肪酸酯的烷氧化衍生物、C1-C30脂肪醇的烷氧化醚、C1-C30脂肪酸的聚甘油醚、C1-C30多元醇酯、C1-C30多元醇醚、烷基磷酸盐、聚氧化烯脂肪醚磷酸盐、脂肪酸酰胺、酰基乳酸盐、皂以及它们的混合物。其它适宜的乳化剂描述于,例如,由Allured Publishing Corporation出版的McCutcheon的“Detergents and Emulsifiers”北美版(1986)、美国专利5,011,681、4,421,769和3,755,560中。
2.
水包油乳液
其它优选的局部用载体包括水包油乳液,其具有连续水相和分散在其中的疏水性水不溶相(“油相”)。“油相”可包含油、硅氧烷或它们的混合物,并且包括但不限于上文油包水乳液部分中所述的油和硅氧烷。乳液表征为水包油乳液还是水包硅氧烷乳液的区别,取决于油相主要是由油还是由硅氧烷组成。这些乳液的水相主要由水组成,但也可包含各种其它成分,如列于上文油包水乳液部分中的那些水相成分。优选的水包油乳液包含按所述整个组合物的重量计约25%至约98%,优选约65%至约95%,更优选约70%至约90%的水。
除了连续的水相和分散的油相或硅氧烷相以外,这些水包油组合物还包含用于稳定乳液的乳化剂。可用于本发明的乳化剂是本领域熟知的,并且包括非离子、阴离子、阳离子和两性乳化剂。可用于本发明水包油乳液中的乳化剂的非限制性实施例可见于由Allured PublishingCorporation出版的McCutcheon的“Detergents and Emulsifiers”北美版(1986)、美国专利5,011,681、美国专利4,421,769和美国专利3,755,560中。
非必需成分
本发明组合物可包含多种既定产品类型中常用的其它组分,前提条件是它们不会不可接受地改变本发明的有益效果。
当组合物中掺入非必需组分时,这些组分应适于与人类的角质组织接触,在合理的判断范围内没有不适当的毒性、不相容性、不稳定性、变应性反应等等。“CTFA Cosmetic Ingredient Handbook”第二版(1992)描述了各种各样的通常用于皮肤护理领域的、适用于本发明组合物的非限制性化妆品和药物成分。这类成分的实施例包括:研磨剂,吸收剂,美感组分如芳香剂、颜料、染色剂/着色剂、精油、皮肤增感剂、收敛剂等(如丁香油、薄荷醇、樟脑、桉树油、丁子香酚、乳酸薄荷酯、金缕梅馏出液),抗痤疮剂,抗结块剂,消泡剂,抗微生物剂(如丁基氨基甲酸碘丙酯),抗氧化剂,粘合剂,生物添加剂,缓冲剂,增量剂,螯合剂,化学添加剂,着色剂,化妆品收敛剂,化妆品杀虫剂,变性剂,药用收敛剂,外用止痛剂,成膜剂或成膜物质如有助于组合物成膜特性和成膜直接性的聚合物(如二十碳烯和乙烯基吡咯烷酮的共聚物),遮光剂,pH调节剂,推进剂,还原剂,多价螯合剂,皮肤美白剂和亮肤剂,皮肤调理剂,皮肤抚慰剂和/或愈合剂以及衍生物,皮肤处理剂,增稠剂,和维生素、以及它们的衍生物。
然而,在本发明的任一实施方案中,可用于本发明的活性物质可通过其提供的有益效果或其假定的作用方式来分类。然而应当理解,在某些情况下,可用于本发明的活性剂可提供一种以上的有益效果或通过一种以上作用方式起作用。因此,本文中的分类仅是为了方便起见,并非旨在将活性物质限制在所列出的特定的一种应用或多种应用中。
1.
脱屑活性物质
可将安全有效量的脱屑活性剂加入到本发明的组合物中,其用量按所述组合物的重量计更优选为约0.01%至约10%,甚至更优选为约0.5%至约5%,还优选为约0.1%至约2%。脱屑活性物质能增强本发明皮肤外观有益效果。例如,脱屑活性物质能改善皮肤肌理(例如,光滑性)。适用于本文的另一个脱屑体系包含水杨酸和两性离子表面活性剂,并被描述于美国专利5,652,228中。如这些申请中所描述的两性离子表面活性剂也可用作本文的脱屑剂,同时尤其优选鲸蜡基甜菜碱。
2.
抗痤疮活性物质
本发明的组合物可包含安全有效量的一种或多种抗痤疮活性物质。有用的抗痤疮活性物质的实施例包括间苯二酚、硫、红霉素、锌、脱氢乙酸等。适宜抗痤疮活性物质的更多的实施例更详细地描述于美国专利5,607,980中。
3.
抗皱纹活性物质/抗萎缩活性物质
本发明的组合物还可包含安全有效量的一种或多种抗皱纹活性物质或抗萎缩活性物质。适用于本发明组合物中的示例性抗皱纹活性物质/抗萎缩活性物质包括羟基酸(如水杨酸、乙醇酸)、酮酸(如丙酮酸)、抗坏血酸(维生素C)、植酸、溶血磷脂酸、类黄酮(如异黄酮、黄酮等)、二苯乙烯、肉桂酸酯、白藜芦醇、激动素、玉米素、二甲基氨乙醇、来自天然源的肽(如大豆肽)、糖酸的盐(如葡萄糖酸锰)和类视色素(其可增强本发明的角质组织外观有益效果,尤其是调节角质组织状况,如皮肤状况)、以及其它维生素B化合物(如硫胺素(维生素B1)、泛酸(维生素B5)、肉毒碱(维生素Bt)、核黄素(维生素B2)、以及它们的衍生物和盐(如HCl盐或钙盐))。
4.
抗氧化剂/自由基清除剂
本发明的组合物可包括安全有效量的抗氧化剂/自由基清除剂。抗氧化剂/自由基清除剂尤其可用于提供保护,以防止可引起脱皮加重或角质层中结构发生改变的紫外线辐射,以及防止可引起皮肤损伤的其它环境试剂。
可将安全有效量的抗氧化剂/自由基清除剂加到本主题发明的组合物中,其用量优选为所述组合物的约0.1%至约10%,更优选约0.01%至约5%。
可使用抗氧化剂/自由基清除剂如抗坏血酸(维生素C)及其盐、脂肪酸的抗坏血酸酯、抗坏血酸衍生物(如抗坏血酸磷酸镁)、生育酚(维生素E)、生育酚山梨酸酯、生育酚乙酸酯、生育酚的其它酯、丁基化羟基苯甲酸和它们的盐、6-羟基-2,5,7,8-四甲基苯并二氢吡喃-2-羧酸(以商品名TroloxR市售)、胺(如N,N-二乙基羟基胺、氨基胍)、去甲二氢愈创木酸、生物类黄酮、氨基酸、水飞蓟素、茶提取物、和葡萄皮/籽提取物。优选的抗氧化剂/自由基清除剂选自生育酚的酯,更优选生育酚乙酸酯。
5.
螯合剂
本发明的组合物还可以包含安全有效量的螯合剂或螯合试剂。本文所用的“螯合剂”或“螯合试剂”是指能通过形成络合物从体系中移除金属离子的活性试剂,这样金属离子就不易参与或催化氧自由基的形成。包含螯合剂尤其可用于防护造成皮肤损伤的紫外线辐射。
可将安全有效量的螯合剂加入到本主题发明的组合物中,其含量按所述组合物的重量计优选为约0.1%至约10%,更优选约1%至约5%。可用于本发明的示例性螯合剂公开于美国专利5,487,884中。可用于本主题发明组合物中的优选螯合剂是糠偶酰二肟及其衍生物。
6.
类黄酮
本发明的组合物可非必需地包含类黄酮化合物。类黄酮被广泛地公开于美国专利5,686,082和5,686,367中。尤其适用于本发明的类黄酮的实施例是一种或多种黄酮、一种或多种异黄酮、一种或多种香豆素、一种或多种色酮、一种或多种双香豆素、一种或多种苯并二氢吡喃-4-酮、一种或多种苯并二氢吡喃醇、它们的异构体(如顺式/反式异构体)以及它们的混合物。
优选可用于本文的是黄酮和异黄酮,具体的讲是黄豆甙原(7,4′-二羟基异黄酮)、三羟基异黄酮(5,7,4’-三羟基异黄酮)、牛尿酚(7,4’-二羟基异黄酮)、5,7-二羟基-4′-甲氧基异黄酮、大豆异黄酮(从大豆中提取的混合物)以及它们的混合物。
可用于本发明的类黄酮化合物市售自多个来源,例如IndofineChemical Company,Inc.,Steraloids,Inc.和Aldrich ChemicalCompany,Inc.。
本文所述类黄酮化合物在本发明中优选以约0.01%至约20%,更优选约0.1%至约10%,甚至更优选约0.5%至约5%的浓度存在。
7.
抗炎剂
可将安全有效量的抗炎剂加到本发明的组合物中,其用量优选为所述组合物重量的约0.01%至约10%,更优选约0.5%至约5%。抗炎剂增强本发明皮肤外观有益效果,例如,这样的试剂有助于使肤质或肤色更均匀并更令人满意。抗炎剂在组合物中的精确用量将取决于所用的具体抗炎剂,因为不同抗炎剂的效力变化很大。
甾族抗炎剂,包括但不限于,皮质类固醇,例如,氢化可的松。可用于本组合物中的第二类抗炎剂包括非甾族抗炎剂。属于非甾族抗炎剂的多种化合物是本领域技术人员所熟知的。用于本发明的组合物的具体的非甾族抗炎剂包括,但不限于,水杨酸酯、氟芬那酸、依托芬那酯、阿司匹林以及它们的混合物。
可用于本发明的其它抗炎剂包括尿囊素和甘草(光果甘草属/种植物)类化合物,包括甘草次酸、甘草酸及其衍生物(例如盐和酯)。
8.
抗蜂窝炎剂
本发明的组合物还可以包含安全有效量的抗蜂窝炎剂。合适的抗蜂窝炎剂包括但不限于黄嘌呤化合物(例如咖啡因、茶碱、可可碱和氨茶碱)。
9.
晒黑活性物质
本发明的组合物可包含晒黑活性物质。当含有晒黑活性物质时,所述组合物优选包含按所述组合物的重量计约0.1%至约20%,更优选约2%至约7%,甚至更优选约3%至约6%的晒黑活性物质。优选的晒黑活性物质是二羟基丙酮。
10.
亮肤剂
本发明的组合物可包含亮肤剂。当使用亮肤剂时,所述组合物优选包含按所述组合物的重量计约0.1%至约10%,更优选约0.2%至约5%,还优选约0.5%至约2%的亮肤剂。适宜的亮肤剂包括本领域已知的那些物质,其包括曲酸、熊果苷、氨甲环酸、抗坏血酸及其衍生物(例如抗坏血酸磷酸镁或抗坏血酸磷酸钠,抗坏血酸基葡糖苷等)。适用于本文的其它亮肤物质包括Acitwhite(Cognis),Emblica(Rona),Azeloglicina(Sinerga)和提取物(如桑树提取物)。
11.
抗微生物和抗真菌活性物质
本发明的组合物可包含抗微生物或抗真菌活性物质。这类活性物质能够破坏微生物,阻止微生物发育或防止微生物的致病作用。安全有效量的抗微生物或抗真菌活性物质可加入到本组合物中,其含量优选为所述组合物重量的约0.001%至约10%,更优选约0.01%至约5%,甚至更优选约0.05%至约2%。
可用于本发明的活性物质的优选实施例包括选自下列物质的那些:水杨酸、过氧化苯甲酰、3-羟基苯甲酸、乙醇酸、乳酸、4-羟基苯甲酸、乙酰基水杨酸、2-羟基丁酸、2-羟基戊酸、2-羟基己酸、顺式-视黄酸、反式-视黄酸、视黄醇、植酸、N-乙酰基-L-半胱氨酸、硫辛酸、壬二酸、花生四烯酸、过氧化苯甲酰、四环素、布洛芬、萘普生、氢化可的松、乙酰氨基苯酚、间苯二酚、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4′-三氯-2′-羟基二苯基酯、3,4,4′-三氯碳酰苯胺、羟甲辛吡酮、环匹罗司、盐酸利多卡因、克霉唑、咪康唑、酮康唑、硫酸新霉素以及它们的混合物。
12.
防晒活性物质
本主题发明组合物可非必需地包含防晒活性剂。本文所用的“防晒活性物质”包括防晒剂和物理防晒霜。合适的防晒活性物质可以是有机的或无机的。
有多种常规防晒活性物质适用于本文。Sagarin等人在“CosmeticsScience and Technology”(1972)的第VIII章,从189页开始至以后的部分中公开了多种合适的活性物质。尤其适宜的防晒剂是对甲氧基肉桂酸-2-乙基己酯(以商品名PARSOL MCX市售)、4,4′-叔丁基甲氧基二苯甲酰甲烷(以商品名PARSOL 1789市售)、2-羟基-4-甲氧基二苯酮、辛基二甲基对氨基苯甲酸、二倍酰三油酸酯、2,2-二羟基-4-甲氧基二苯酮、4-(二(羟丙基))氨基苯甲酸乙酯、2-氰基-3,3-二苯基丙烯酸-2-乙基己酯、水杨酸-2-乙基己酯、对氨基苯甲酸甘油酯、3,3,5-三甲基环己基水杨酸酯、氨茴酸甲酯、对二甲基氨基苯甲酸或氨基苯甲酸酯、对二甲基氨基苯甲酸-2-乙基己酯、2-苯基苯并咪唑-5-磺酸、2-(对二甲基氨基苯基)-5-磺酸苯并噁唑酸、氰双苯丙烯酸辛酯、氧化锌、二氧化钛,以及这些化合物的混合物。
可用于本主题发明组合物中的优选的有机防晒活性物质是对甲氧基肉桂酸-2-乙基己酯、丁基甲氧基二苯甲酰基甲烷、2-羟基-4-甲氧基二苯甲酮、2-苯基苯并咪唑-5-磺酸、辛基二甲基对氨基苯甲酸、氰双苯丙烯酸辛酯、氧化锌、二氧化钛以及它们的混合物。尤其优选的防晒活性物质包括4,4’-叔丁基甲氧基二苯甲酰甲烷、对甲氧基肉桂酸-2-乙基己酯、苯基苯并咪唑磺酸、氰双苯丙烯酸辛酯、氧化锌和二氧化钛以及它们的混合物。
使用安全有效量的防晒活性剂,其用量典型地为所述组合物重量的约1%至约20%,更典型地为约2%至约10%。其准确用量将取决于所选的防晒剂以及所需的防晒因子(SPF)。
13.
调节剂
本发明的组合物可包含选自湿润剂、增湿剂或皮肤调节剂的调节剂。可使用多种这些物质,并且每种的含量可以为所述组合物重量的约0.01%至约40%,更优选约0.1%至约30%,甚至更优选约0.5%至约15%。这些物质包括但不限于,胍,脲,乙醇酸和乙醇酸盐(例如铵和四烷基铵),乳酸和乳酸盐(例如铵和四烷基铵),任何形式的芦荟(例如芦荟凝胶),多羟基化合物如山梨醇、甘露糖醇、甘油、己三醇、丁三醇、丙二醇、丁二醇、己二醇等,聚乙二醇,糖(例如蜜二糖)和淀粉,糖和淀粉衍生物(例如烷氧基化葡萄糖、果糖、蔗糖等),透明质酸,乳酸胺单乙醇胺,乙酰胺单乙醇胺,蔗糖聚酯,凡士林以及它们的混合物。
调理剂优选选自甘油、脲、凡士林、蔗糖聚酯以及它们的组合。
14.
增稠剂(包括增稠剂和胶凝剂)
本发明组合物可包含一种或多种增稠剂,其含量优选为所述组合物重量的约0.05%至约10%,更优选约0.1%至约5%,甚至更优选约0.25%至约4%。
增稠剂的非限制性种类包括选自如下物质的那些:
a.
羧酸聚合物
这些聚合物是交联化合物,其包含一个或多个衍生自丙烯酸、取代丙烯酸和这些丙烯酸以及取代丙烯酸的盐和酯的单体,其中交联剂含有两个或更多个碳-碳双键,并衍生自多元醇。
可用于本发明的市售羧酸聚合物的实施例包括卡波姆,其是丙烯酸与蔗糖或季戊四醇烯丙基醚交联形成的均聚物。卡波姆以商品名Carbopol900系列得自B.F.Goodrich(例如Carbopol954)。另外,其它合适的羧酸聚合剂包括C10-30丙烯酸烷基酯与一种或多种下列单体的共聚物,所述单体包括:丙烯酸、异丁烯酸、或它们的短链(即C1-4醇)酯,其中交联剂是蔗糖或季戊四醇的烯丙基醚。这些共聚物称为丙烯酸酯/C10至30丙烯酸烷基酯交联聚合物,且以商品名Carbopol1342、Carbopol1382、Pemulen TR-1和Pemulen TR-2购自B.F.Goodrich。换句话讲,可用于本发明的羧酸聚合物增稠剂的实施例选自卡泊姆、丙烯酸酯/C10-C30丙烯酸烷基酯交联聚合物以及它们的混合物的那些。
b.
交联聚丙烯酸酯聚合物
本发明的组合物可非必需地包含用作增稠剂或胶凝剂的交联聚丙烯酸酯聚合物,包括阳离子和非离子聚合物,通常优选阳离子聚合物。有用的交联非离子聚丙烯酸酯聚合物和交联阳离子聚丙烯酸酯聚合物的实施例是描述于以下的那些:美国专利5,100,660、美国专利4,849,484、美国专利4,835,206、美国专利4,628,078、美国专利4,599,379和EP 228,868。
c.
聚丙烯酰胺聚合物
本发明的组合物可非必需地包含聚丙烯酰胺聚合物,尤其是非离子聚丙烯酰胺聚合物,包括取代的支链或无支链聚合物。这些聚丙烯酰胺聚合物中,优选的是CTFA命名为聚丙烯酰胺、异链烷烃和月桂基聚氧乙烯醚-7的非离子聚合物,其以商品名Sepigel 305购自SeppicCorporation。
可用于本发明的其它聚丙烯酰胺聚合物包括丙烯酰胺和取代的丙烯酰胺与丙烯酸和取代的丙烯酸的多嵌段共聚物。这些多嵌段共聚物的市售实施例包括购自Lipo Chemicals,Inc.的Hypan SR150H、SS500V、SS500W和SSSA100H。
d.
多糖
有多种多糖可用于本发明。“多糖”是指含有重复糖(即碳水化合物)单元主链的胶凝剂。多糖胶凝剂的非限制性实施例包括选自纤维素、羧甲基羟乙基纤维素、乙酸-丙酸-羧酸纤维素、羟乙基纤维素、羟乙基乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、甲基羟乙基纤维素、微晶纤维素、纤维素硫酸钠以及它们的混合物的那些。还可用于本发明的是烷基取代的纤维素。在烷基羟基烷基纤维素醚当中,优选的是按CTFA命名为鲸蜡基羟乙基纤维素的物质,它是鲸蜡醇与羟乙基纤维素的醚。该物质以商品名NatrosolCS Plus由Aqualon Corporation出售。
其它可使用的多糖包括小核菌葡聚糖,其包含一条(1-3)连接的葡萄糖单元的直链,每3个单元具有一个(1-6)连接的葡萄糖,其市售的实施例是购自Michel Mercier Products Inc.的ClearogelTMCS11。
e.
树胶
其它可用于本发明的增稠剂和胶凝剂包括主要得自天然源的物质。这些胶凝剂树胶的非限制性实施例包括选自下列的物质:金合欢、琼脂、褐藻胶、藻酸、藻酸铵、支链淀粉、藻酸钙、角叉菜胶钙、肉毒碱、角叉菜胶、糊精、明胶、结冷胶、瓜耳胶、瓜尔胶羟基丙基三甲基氯化铵、锂蒙脱石、透明质酸、二氧化硅水合物、羟丙基脱乙酰壳多糖、羟丙基瓜耳胶、刺梧桐树胶、海藻、刺槐豆胶、纳豆胶、藻酸钾、角叉菜胶钾、丙二醇藻酸盐、菌核胶、羧甲基葡聚糖钠、角叉菜胶钠、黄蓍胶、黄原胶以及它们的混合物。
15.
水溶性维生素
本发明组合物可包含安全有效量的一种或多种水溶性维生素。水溶性维生素的实施例包括,但不限于,水溶性的维生素B、维生素B衍生物、维生素C、维生素C衍生物、维生素K、维生素K衍生物、维生素D、维生素D衍生物、维生素E、维生素E衍生物以及它们的混合物。维生素化合物可作为基本上纯的物质使用,或者作为通过合适的物理和/或化学分离手段从天然(例如植物)来源获得的提取物来使用。当本发明组合物中含有维生素化合物时,该组合物优选包含按所述组合物的重量计约0.0001%至约50%,更优选约0.001%至约10%,还更优选约0.01%至约5%,还更优选约0.1%至约5%的维生素化合物。
16.
颗粒物质
本发明的组合物可包含一种或多种颗粒物质。可用于本发明中的颗粒物质的非限制性实施例包括有色和无色颜料、干涉颜料、无机粉末、有机粉末、复合粉末、荧光增白剂颗粒以及它们的组合。这些颗粒可以是片状的、球状的、细长的或针状的,或不规则形状的,表面被涂层或未被涂层,多孔或无孔的,带电荷或不带电荷,并且可作为粉末或预分散体加入到本发明的组合物中。这些颗粒物质可提供多种功能,包括但不限于,调节皮肤感觉,遮掩某些皮肤特征外观如疤面、老年斑、雀斑、细纹、皱纹和毛孔,吸收过剩的皮脂/油脂,降低皮肤光泽,改善组合物的适用性,掩蔽组合物其它组分的颜色,填充皮肤的毛孔、细纹和皱纹,以及减少皮肤上液体物质的流动。优选地,颗粒物质在组合物中的含量为所述组合物重量的约0.01%至约20%,更优选约0.05%至约10%,还更优选约0.1%至约5%。对用于组合物中所用的颜料、着色剂或填充剂粉末,没有具体的限制。
可用于本发明的颗粒物质包括但不限于,氯氧化铋、绢云母、云母、用硫酸钡或其它物质处理过的云母、沸石、高岭土、二氧化硅、氮化硼、月桂酰赖氨酸、尼龙、聚乙烯、滑石、苯乙烯、聚丙烯、聚苯乙烯、乙烯/丙烯酸共聚物、绢云母、氧化铝、硅氧烷树脂、硫酸钡、碳酸钙、醋酸纤维素、PTFE、聚甲基丙烯酸甲酯、淀粉、改性淀粉如铝淀粉琥珀酸辛烯酯、丝、玻璃以及它们的混合物。优选的有机粉末/填充剂包括但不限于,选自甲基倍半硅氧烷树脂微球体的聚合物颗粒,如,例如以商品名Tospearl 145A由Toshiba silicone出售的那些;聚甲基丙烯酸甲酯微球体,如以商品名Micropearl M 100由Seppic出售的那些;交联聚二甲基硅氧烷的球状颗粒,尤其是例如以商品名Trefil E506C或Trefil E 505C由Dow Corning Toray Silicone出售的那些;聚酰胺球状颗粒,且更具体地讲是尼龙12,尤其是例如以商品名Orgasol 2002D Nat C05由Atochem出售的那些;聚苯乙烯微球体,如,例如以商品名Dynospheres由Dyno Particles出售的那些;乙烯丙烯酸酯共聚物,以商品名FloBead EA209由Kobo出售;PTFE;聚丙烯;铝淀粉琥珀酸辛烯酯,如以商品名Dry Flo由NationalStarch出售的那些;聚乙烯微球体,如以商品名Microthene FN510-00由Equistar出售的那些;硅氧烷树脂;聚甲基倍半硅氧烷硅氧烷聚合物;由L-月桂酰赖氨酸制成的片状粉末以及它们的混合物。尤其优选的是球状粉末,其平均主要粒径为0.1至75微米,优选0.2至30微米。
干涉颜料也可用于本文中。对本发明说明书而言,干涉颜料定义为薄层状层化颗粒,其具有两个或多个具有不同折射率的可控制厚度的层,由典型两层、但有时多层光反射的干涉作用产生特征反射色,形成不同的层状颗粒层。干涉颜料的最常见实施例是云母,以约50-300nm的TiO2、Fe2O3、二氧化硅、氧化锡和/或Cr2O3薄膜夹层。上述颜料通常是具有珍珠般的光泽的。由于颜料颗粒的透明性以及云母片与(例如)二氧化钛涂层间折射指数的巨大差别,珠光着色剂可反射、折射和透射光线。可用的干涉颜料由众多供应商市售,例如,Rona(TimironTM和DichronaTM),Presperse(FlonacTM),Englehard(DuochromeTM),Kobo(SK-45-R和SK-45-G),BASF(Sicopearls)和Eckart(如Prestige Silk Red)。尤其优选的是具有较小粒径的干涉颜料,单个颗粒在最长方向上具有的平均直径小于约75微米,优选小于约50微米。
可用于本发明中的其它颜料,主要通过选择性地吸收特定波长的可见光而提供颜色,并且包括无机颜料、有机颜料以及它们的组合。有用的无机颜料的实施例包括氧化铁、氰亚铁酸铵铁、锰紫、群青和铬绿。有机颜料可包括天然的着色剂和合成的单体着色剂以及聚合物着色剂。一个实施例是酞菁蓝和酞菁绿颜料。还有用的是色淀,主要是FD&C或D&C色淀,以及它们的共混物。还有用的是胶囊包封的可溶性或不溶性染料以及其它着色剂。可用于本发明的无机白色颜料或无色颜料,例如TiO2、ZnO或ZrO2,可市售自多个来源。适宜颗粒物质的一个实施例包含购自U.S.Cosmetics的物质(TRONOX TiO2系列,SAT-T CR837,金红石TiO2)。尤其优选二氧化钛的带电分散体,如美国专利5,997,887中所公开的。
优选的有色或无色非干涉类型的颜料所具有的主要平均粒径为约10nm至约100,000nm,更优选约20nm至约5,000nm,甚至更优选约20nm至约1000nm。具有不同粒径的相同或不同颜料/粉末的混合物也可用于本发明(例如,将具有主要粒径为约10nm至约50nm的TiO2掺入到具有主要粒径为约100nm至约400nm的TiO2中)。
本发明的颜料/粉末可进行表面处理,以提供附加的色彩稳定性和/或制剂的容易性。适宜包衣材料的非限制性实施例包括硅氧烷、卵磷脂、氨基酸、金属皂、聚乙烯和胶原。这种表面处理可以是疏水的或亲水的,优选进行疏水处理。尤其有用的疏水性颜料处理包括聚硅氧烷处理,如公开于美国专利5,143,722中的那些。
组合物形式
包括但不限于露剂、乳液、摩丝、浆液、喷剂、气溶胶、泡沫、棒状物、笔剂、凝胶、霜膏和油膏剂的本主题发明的局部组合物,可包含皮肤病学可接受的润肤剂。这样的组合物优选包含约2%至约50%的润肤剂。本文所用的“润肤剂”是指可用于预防或缓解干燥、以及保护皮肤的物质。多种合适的润肤剂是已知的,并且可用于本发明。Sagarin的“Cosmetics,Science and Technology”第二版第1卷第32-43页(1972),包含了许多适于用作润肤剂的物质的实施例。优选的润肤剂是甘油。甘油的用量优选为所述组合物重量的约0.001%至约20%,更优选约0.01%至约15%,甚至更优选约0.1%至约10%。
可用于清洁的本发明组合物(“清洁剂”)是用适宜的载体(例如,如上所述的载体,并且包含按所述组合物的重量计约1%至约90%的皮肤病学可接受的表面活性剂)配制的。
清洁组合物的物理形式并不十分重要。所述组合物可以配制成如香皂、清洁液、洗发剂、沐浴凝胶、毛发调理剂、生发油、糊剂或摩丝等形式。优选香皂,因为这种形式的清洁剂最常用于洗涤皮肤。洗去型清洁组合物,例如洗发剂,需要有递送系统来沉积足够含量的活性物质到皮肤和头皮上。优选的递送系统包括使用不溶性配合物。至于上述递送体系的更完整的公开内容,参见美国专利4,835,148。
本发明组合物也可为化妆品的形式。合适的化妆品形式包括但不限于粉底、唇膏、胭脂、睫毛膏等等。这种化妆品可包括常规成分,例如油剂、着色剂、颜料、润肤剂、芳香剂、蜡、稳定剂等等。示例性载体和适用于本文的上述其它成分被描述于,例如,美国专利6,060,547中。
组合物的制备
本发明组合物通常通过常规方法制备,如本领域已知的制备局部组合物的方法。这些方法典型地包括在一个或多个步骤中将成分混合至比较均一的状态,可需要或不需要加热、冷却、使用真空等条件。优选这样制备该组合物,以使得稳定性(物理稳定性、化学稳定性、光稳定性)最优化和/或活性物质(如N-酰基氨基酸、糖胺、维生素B3、类视色素、植物甾醇、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸)的递送最优化。这种最优化可包括合适的pH值(如小于7)、排除可与活性物质复合并因而负面影响到稳定性或递送的物质(如排除杂质铁)、使用预防复合物生成的方法(如合适的分散剂或双层包装)、使用合适的光稳定性方法(如加入防晒油/防晒霜、使用不透明的包装),等等。
调节角质组织状况的方法
本发明组合物用于调节许多哺乳动物的角质组织状况。这类角质组织状况的调节包括预防性调节和处理性调节。更具体地讲,上述调节方法涉及但不限于,增厚角质组织(即构造皮肤的表皮层和/或真皮层和/或皮下层,且这里适用于指甲和毛干的角质层),通过用作亮白或减轻色素沉着的美容剂预防、延迟和/或处理不均匀的肤色,预防、延迟和/或处理哺乳动物皮肤的萎缩,软化和/或平滑哺乳动物的嘴唇、毛发和指甲,预防、延迟和/或处理哺乳动物皮肤的瘙痒,预防、延迟和/或处理黑眼圈和/或肿眼的出现,预防、延迟和/或处理哺乳动物肤色灰黄,预防、延迟和/或处理哺乳动物皮肤松垂(即糖化作用),预防和/或延迟哺乳动物皮肤晒黑、脱屑、脱皮和/或增加哺乳动物皮肤中的更新,减小哺乳动物皮肤中的毛孔尺寸,调节哺乳动物皮肤的油性/光泽外观,预防、延迟和/或处理色素沉着过度如发炎后色素沉着过度,预防、延迟和/或处理哺乳动物皮肤上的蛛形血管和/或红斑的出现,预防、延迟和/或处理哺乳动物皮肤的细纹和皱纹,预防、延迟和/或处理皮肤干燥(即粗糙、脱皮、剥落)以及预防、延迟和/或处理哺乳动物皮肤中蜂窝炎的出现。
申请者现已惊奇地发现,基本上由所选的N-酰基氨基酸化合物所组成的本发明组合物也可用于上述公开的方法。
调节角质组织状况包括向角质组织局部应用安全有效量的本发明组合物。应用组合物的量、应用频率和使用周期将根据所给组合物中N-酰基氨基酸和/或其它组分的含量和所需的调节水平而有很大不同,所述调节水平,如按照现有或期望出现的角质组织损害程度。
在一个优选的实施方案中,所述组合物长期应用于皮肤。“长期局部应用”是指在个体的一生中长期持续地局部应用组合物,优选时间为至少约一个星期,更优选至少约一个月,甚至更优选至少约三个月,甚至更优选至少约六个月,还甚至更优选至少约一年。尽管有益效果在各种不同的最大使用期(例如五、十或二十年)后仍能获得,但优选在个体整个一生中都长期持续应用。在这长时间中,典型地依照每天约一次的规律应用,然而应用频率可以在约每周一次至约每天三次或更多次的范围内变化。
本发明组合物的各种用量可被用来提供皮肤外观和/或皮肤感觉的有益效果。以mg组合物/cm2皮肤计,本组合物每次典型施用的量为约0.1mg/cm2至约20mg/cm2。尤其有用的用量为约0.5mg/cm2至约10mg/cm2。
可优选施用皮肤乳液、清爽乳液、牛奶乳液、霜膏、凝胶、泡沫、油膏剂、糊剂、乳液、喷剂、调理剂、滋补剂、化妆品、唇膏、粉底、指甲油、须后水等形式的组合物,以调节角质组织状况,所述组合物旨在留于皮肤或其它角质组织上,以达到某些美学上的、预防上的、处理上的或其它方面的有益效果(即“免洗型”组合物)。在角质组织(如皮肤)上施用组合物后,其留在皮肤上优选至少约15分钟,更优选至少约30分钟,甚至更优选至少约1小时,甚至更优选至少几小时,如最多约12小时。可以处理面部、毛发和/或指甲的任何表面部位,例如,面部、嘴唇、眼下部位、眼皮、头皮、颈、躯干、臂、手、腿、手指甲、脚趾甲、头发、睫毛、眉毛等。可使用如手掌和/或手指、器具如棉球、药签、软垫等,施用本发明的组合物。
确保将至少最小含量的N-酰基氨基酸连续涂敷在角质组织上的另一个方法是使用贴剂来将化合物施用到例如脸上。这种方法尤其可用于有问题的皮肤区域,该皮肤区域需要更多的强化处理(如面部鱼尾纹区域、眉心纹、眼下区域等等)。贴剂可以是闭合的、半闭合的或非闭合的。N-酰基氨基酸组合物可包含于贴剂中,或在使用贴剂前涂敷于皮肤上。该贴剂还可包含附加活性物质,如用于放热反应的化学引发剂,如PCT申请WO 9701313中所描述的那些。该贴剂还可包含电能源(如电池)以,例如,增加N-酰基氨基酸和其它活性剂的递送(如离子电渗疗法)。贴剂敷在角质组织上的保留时间优选至少约5分钟,更优选至少约15分钟,还更优选至少约30分钟,甚至更优选至少约1小时,甚至更优选晚上作为夜间处理的一种形式。
实施例
下列是本发明组合物的非限制性实施例。实施例的给出仅是为了举例说明之目的,不应被解释为是对本发明的限制,因为在不背离本发明的精神和范围的情况下,其许多改变是可能的,这将被本领域的普通技术人员所认识到。在实施例中,除非另外指明,所有浓度均以重量百分比列出,并排除了次要物质,如稀释剂、填充剂等。因此,所列制剂包括所列组分和任何与该组分相关的次要物质。对本领域普通的技术人员来说显而易见的是,这些次要组分的选定将根据选定的具体成分的物理和化学特性而不同,以制造本文所述的发明。
实施例I-VI
通过传统方法,用以下组分制备皮肤保湿霜膏/露剂。
组分 | I | II | III | IV | V | VI | |
相A | |||||||
水 | 适量 | 适量 | 适量 | 适量 | 适量 | 适量 | |
甘油 | 5.0000 | 7.0000 | 7.0000 | 10.0000 | 5.0000 | 7.0000 | |
苯基苯并咪唑磺酸 | 0 | 0 | 0 | 0 | 1.2500 | 0 | |
乙二胺四乙酸二钠 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | |
尿囊素 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.0000 | |
N-十一碳烯酰基-L-苯基丙氨酸 | 1.0000 | 0.5000 | 2.0000 | 0.7500 | 1.5000 | 2.0000 | |
N-乙酰氨基葡糖 | 2.5000 | 2.5000 | 0.0000 | 0.0000 | 5.0000 | 0.0000 | |
去氧苯比妥羟乙基磺酸盐 | 0.1000 | 0.3000 | 1.0000 | 0 | 0 | 0 | |
三乙醇胺 | 0.4 | 0.20 | 0.80 | 0.30 | 1.35 | 0.8000 | |
偏亚硫酸氢钠 | +0.1000 | 0.2000 | 0.1000 | 0.1000 | 0.1000 | 0.0000 | |
BHT | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 0.0150 | 0.0000 | |
二氧化钛(1) | 0.2500 | 0.4500 | 0.4500 | 0.7500 | 0.5500 | 0.6040 | |
烟酰胺 | 0 | 2.0000 | 2.0000 | 3.5000 | 5.0000 | 5.0000 | |
右旋泛醇 | 0.25 | 0.5000 | 1.0000 | 2.0000 | 1.0000 | 1.0000 | |
棕榈酰-五肽(2) | 0 | 0 | 0.0004 | 0 | 0.0003 | 0.0003 | |
相B | |||||||
C12-C15苯甲酸烷基酯 | 5.00 | 2.5000 | 1.5000 | 2.5000 | 0 | 0 | |
辛酸/癸酸甘油三酯 | 1.0 | 1.5000 | 1.5000 | 1.5000 | 1.5000 | 0 | |
水杨酸辛酯 | 0 | 0 | 0 | 0 | 5.0000 | 0 | |
氰双苯丙烯酸辛酯 | 0 | 0 | 0 | 0 | 1.0000 | 0 |
丁基甲氧基二苯甲酰甲烷 | 0 | 0 | 0 | 0 | 2.0000 | 0 |
二棕榈酰羟脯氨酸 | 0 | 0 | 1.0000 | 0 | 0 | 0.50 |
鲸蜡醇 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | 0.5000 |
生育酚乙酸酯 | 0 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | 0.5000 |
脱水山梨醇硬脂酸酯/蔗糖椰油酸酯 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 |
鲸蜡基葡糖苷/鲸蜡醇 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | 0.5000 | 0.5000 |
硬脂醇 | 0.7000 | 0.7000 | 0.7000 | 0.7000 | 0.7000 | 0.7000 |
二十二醇 | 0.6000 | 0.6000 | 0.6000 | 0.6000 | 0.6000 | 0.6000 |
对羟基苯甲酸乙酯 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 |
对羟基苯甲酸丙酯 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 |
PEG-100硬脂酸酯 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 |
蔗糖聚棉子酸酯 | 0 | 0 | 0 | 0 | 0 | 0.6700 |
异十六烷 | 0 | 0 | 0 | 0 | 0 | 3.0000 |
水杨酸 | 1.5 | 0 | 0 | 0 | 0 | 0 |
PPG 15硬脂基醚 | 4 | 0 | 0 | 0 | 0 | 0 |
异硬脂酸异丙酯 | 0 | 0 | 0 | 0 | 0 | 1.3300 |
聚甲基倍半硅氧烷 | 0.2500 | 0.5000 | 1.5000 | 0.5000 | 0.2500 | 0.2500 |
相C | ||||||
聚丙烯酰胺/C13-14异链烷烃/月桂基聚氧乙烯醚-7 | 2.000 | 2.2500 | 2.5000 | 2.5000 | 3.0000 | 2.5000 |
相D | ||||||
丙酸视黄酯 | 0.0000 | 0.0000 | 0.1000 | 0.0000 | 0 | 0 |
植物甾醇 | 1.0000 | 0 | 0.5000 | 0.0000 | 0.0000 | 0 |
绿茶提取物 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0 | 0 |
苄醇 | 0.2500 | 0.2500 | 0.2500 | 0.2500 | 0.2500 | 0.4000 |
聚二甲基硅氧烷/聚二甲基硅氧烷醇 | 0.5 | 1.0000 | 2.5000 | 0.2500 | 2.0000 | 2.0000 |
香料 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 |
(1)所用的二氧化钛是二氧化钛共混于水、甘油、聚丙烯酸铵、对羟基苯甲酸甲酯和对羟基苯甲酸丙酯的共混物中所形成的共混物。
(2)棕榈酰-五肽=棕榈酰-赖氨酸-苏氨酸-苏氨酸-赖氨酸-丝氨酸,购自Sederma。
在一个合适的容器中,将相A组分用合适的搅拌器(如TekmarRW20DZM)混合和搅拌,且搅拌下加热至约70℃至80℃,并保持该温度。在另一个合适的容器中,将相B组分用合适的搅拌器混合和搅拌,且搅拌下加热至约70℃至75℃,并保持该温度。然后将相B混合物加入到相A混合物中并混合均匀,以至使该组合物乳化。接着,将相A和相B组分的乳液冷却至约60℃,然后在连续搅拌下将相C组分加入到乳液中。接着将相A、相B和相C组分的乳液进一步冷却至约40℃,然后在搅拌下将相D组分加入到乳液中。接着,用合适的研磨机(TekmarT-25)研磨所得乳液约5分钟,或直至产物均匀。
实施例VII-XI
通过传统方法,用以下组分制备皮肤保湿霜膏/露剂。
组分 | VII | VIII | IX | X | XI |
相A | |||||
水 | 适量 | 适量 | 适量 | 适量 | 适量 |
尿囊素 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 |
乙二胺四乙酸二钠 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 |
对羟基苯甲酸乙酯 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 |
对羟基苯甲酸丙酯 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 |
BHT | 0.0150 | 0.0150 | 0.015 | 0.0150 | 0.0150 |
右旋泛醇 | 1.0000 | 0.5000 | 1.0000 | 1.0000 | 1.0000 |
甘油 | 7.5000 | 10.000 | 15.000 | 7.5000 | 5.0000 |
N-十一碳烯酰基-L-苯基丙氨酸 | 2.0000 | 0.5 | 1.0000 | 4.0000 | 1.0000 |
去氧苯比妥羟乙基磺酸盐 | 0.0000 | 0.1000 | 0.1000 | 0.0000 | 1.0000 |
烟酰胺 | 0 | 3.5000 | 5.0000 | 2.0000 | 2.0000 |
棕榈酰-五肽(1) | 0 | 0 | 0 | 0.0004 | 0.0003 |
苯基苯并咪唑磺酸 | 0 | 0 | 0 | 0 | 1.0000 |
苄醇 | 0.2500 | 0.2500 | 0.2500 | 0.2500 | 0.2500 |
三乙醇胺 | 0.8 | 0.2 | 0.40 | 1.60 | 1.0 |
绿茶提取物 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 |
N-乙酰氨基葡糖 | 0.0000 | 5.0000 | 2.0000 | 1.0000 | 5.0000 |
偏亚硫酸氢钠 | 0.1000 | 0.1000 | 0.1000 | 0.1000 | 0.1000 |
相B | |||||
环戊硅氧烷 | 15.000 | 15.000 | 18.000 | 15.000 | 15.000 |
二氧化钛 | 0.5000 | 0.5000 | 0.7500 | 0.5000 | 0.5000 |
相C | |||||
C12-C15苯甲酸烷基酯 | 1.5000 | 0 | 0 | 1.5000 | 1.5000 |
二棕榈酰羟脯氨酸 | 0 | 1.0000 | 0 | 0 | 1.0000 |
水杨酸 | 1.5 | 0 | 0 | 0 | 0 |
PPG-15硬脂基醚 | 4 | 0 | 0 | 0 | 0 |
维生素E乙酸酯 | 0.5000 | 0 | 1.0000 | 0.5000 | 0.5000 |
丙酸视黄酯 | 0.000 | 0 | 0 | 0.2000 | 0.2000 |
植物甾醇 | 0.0000 | .0000 | 1.0000 | 5.0000 | 3.0000 |
相D | |||||
KSG-21硅氧烷弹性体(2) | 4.0000 | 4.0000 | 5.0000 | 4.0000 | 4.0000 |
Dow Corning 9040硅氧烷弹性体 | 15.000 | 15.000 | 12.000 | 15.000 | 15.000 |
Abil EM-97聚二甲基硅氧烷共聚多元醇(3) | 0.5000 | 0 | 0 | 0.5000 | 0.5000 |
聚甲基倍半硅氧烷 | 2.5000 | 2.5000 | 2.0000 | 2.5000 | 2.5000 |
芳香剂 | 0.2000 | 0.2000 | 0.2000 | 0.2000 | 0.2000 |
(1)棕榈酰-五肽=棕榈酰-赖氨酸-苏氨酸-苏氨酸-赖氨酸-丝氨酸,购自Sederma。
(2)KSG-21,一种乳化的硅氧烷弹性体,购自Shin Etsu。
(3)Abil EM-97,购自Goldschmidt Chemical Corporation。
在一个合适的容器中,将相A组分用合适的搅拌器(如Tekmarmodel RW20DZM)混合在一起,并持续搅拌直至所有组分都溶解。接着,在合适的容器中,将相B组分混合在一起,并用合适的研磨机(如Tekmar RW-20)研磨约5分钟。接着,搅拌下将相C组分加入到相B混合物中。接着,将相D组分加入到相B和相C的混合物中,然后用合适的搅拌器(如Tekmar RW-20)将所得的相B、C和D组分的组合搅拌约1小时。接着,搅拌下将相A缓慢的加入到相B、C和D的混合物中。接着,将所得混合物持续搅拌直至产物均匀。接着,用合适的研磨机(如Tekmar T-25)将所得产物研磨约5分钟。
实施例XII-XVII:
通过常规的方法,可由以下组分制备保湿水包硅氧烷霜膏/露剂:
XII | XIII | XIV | XV | XVI | XVII | |
水相: | ||||||
水 | 适量 | 适量 | 适量 | 适量 | 适量 | 适量 |
甘油 | 3 | 5 | 7 | 10 | 15 | 10 |
乙二胺四乙酸二钠 | 0.1 | 0.1 | 0.05 | 0.1 | 0.1 | 0.1 |
烟酰胺 | 0 | 0.5 | 3.5 | 3 | 5 | 3 |
N-十一碳烯酰基-L-苯基丙氨酸 | 1 | 0.5 | 2 | 0.75 | 1.0 | 2 |
三乙醇胺 | 0.4 | 0.2 | 0.8 | 0.3 | 0.6 | 0.8 |
D-泛醇 | 0.5 | 0.1 | 1.0 | 0.5 | 1.5 | 0.5 |
GLW75CAP-MP(75%的TiO2含水分散体)1 | ---- | 0.4 | ---- | ---- | ---- | ---- |
羟乙磺酸去氧苯比妥 | 0 | 0.1 | ---- | 1.0 | 0.1 | ---- |
棕榈酰-五肽2 | ---- | ---- | ---- | ---- | 0.0003 | ---- |
N-乙酰氨基葡糖 | 0 | ---- | 2 | ---- | 5 | ---- |
硅氧烷/油相: | ||||||
环状聚甲基硅氧烷D5 | 10 | 5 | 5 | 10 | 7.5 | 10 |
Dow Corning 9040硅氧烷弹性体3 | ---- | 10 | 5 | 5 | 7.5 | 5 |
KSG-15AP硅氧烷弹性体4 | 5 | ---- | 5 | 5 | 7.5 | 5 |
聚二甲基硅氧烷/聚二甲基硅氧烷醇 | ---- | 2 | 2 | 1 | 2 | 1 |
聚二甲基硅氧烷5×10-5m2/s(50csk) | 1 | ---- | ---- | ---- | ---- | ---- |
氧化锌 | 0 | 0 | 0 | 0 | 0 | 3 |
丙酸视黄酯 | 0 | 0.2 | 0 | 0 | 0.1 | 0 |
水杨酸 | 1.5 | 0 | 0 | 0 | 0 | 0 |
PPG 15硬脂基醚 | 4 | |||||
植物甾醇 | ---- | ---- | ---- | 0.1 | ---- | 0.1 |
维生素E乙酸酯 | ---- | 0.5 | 0.1 | 0.1 | ---- | 0.1 |
增稠剂: | ||||||
聚丙烯酰胺/C13-14异链烷烃/月桂基聚氧乙烯醚-7 | 2.5 | 2.5 | ---- | ---- | 3 | |
丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物/异十六烷/聚山梨酸酯80 | ---- | ---- | ---- | 3 | ---- | ---- |
丙烯酸酯/C10-30丙烯酸烷基酯交联聚合物 | ---- | ---- | 0.6 | ---- | 0.5 | ---- |
二棕榈酰羟脯氨酸-预混物: | ||||||
水 | 0 | 0 | 8.85 | 0 | 4.40 | 0 |
三乙醇胺 | 0 | 0 | 0.15 | 0 | 0.075 | 0 |
二棕榈酰羟脯氨酸 | 0 | 0 | 1 | 0 | 0.50 | 0 |
附加成分: | ||||||
三乙醇胺 | ---- | ---- | ---- | ---- | 0.6 | ---- |
聚四氟乙烯 | ---- | 0.5 | ---- | ---- | ---- | ---- |
聚甲基倍半硅氧烷 | ---- | 0.5 | 1.0 | ---- | ---- | ---- |
聚乙烯 | ---- | 0.5 | ---- | ---- | 1.0 | ---- |
Flamenco Summit Green G30D5 | ---- | ---- | 1.0 | ---- | ---- | ---- |
Prestige Silk Red6 | ---- | ---- | ---- | 1.0 | 1.0 | 1.0 |
总量: | 100% | 100% | 100% | 100% | 100% | 100% |
1GLW75CAP-MP,75%的二氧化钛含水分散体,购自Kobo
2棕榈酰-赖氨酸-苏氨酸-苏氨酸-赖氨酸-丝氨酸,购自Sederma
3硅氧烷弹性体分散体,购自Dow Corning Corp.
4硅氧烷弹性体分散体,购自Shin Etsu
5二氧化钛和二氧化锡涂层云母绿色干涉颜料,购自Engelhard
6二氧化钛涂层云母红色干涉颜料,购自Eckart
在一个适宜的容器中,合并水相成分,并混合直至均匀。在一个单独的适宜容器中,合并硅氧烷/油相成分,并混合直至均匀。通过在一个适宜的容器中混合预混物成分,在搅拌的同时加热至约70℃,然后在搅拌的同时冷却至室温,分步制备二棕榈酰羟脯氨酸预混物(若含有的话)。加入一半增稠剂,然后将硅氧烷/油相加入到水相中,并研磨所得乳液(如用Tekmar T-25)。加入剩余的增稠剂、二棕榈酰羟脯氨酸预混物(若含有的话),然后在搅拌的同时将剩余成分加入到乳液中。一旦该组合物均匀,则将产品倒入到适宜容器中。
尽管已用具体实施方案来说明和描述了本发明,但对于本领域的技术人员显而易见的是,在不背离本发明的精神和保护范围的情况下可作出许多其它的变化和修改。因此,有意识地在附加的权利要求书中包括本发明范围内的所有这些变化和修改。
发明背景、发明概述和发明详述中所有引用的文献的相关部分均引入本文以供参考;任何文献的引用并不可解释为是对其作为本发明的现有技术的认可。
Claims (10)
1.一种护肤组合物,所述护肤组合物包含:
a)N-酰基氨基酸化合物,所述化合物选自N-酰基氨基酸,它们的异构体,它们的盐,它们的衍生物、或它们的混合物;
b)安全有效量的护肤活性物质,所述护肤活性物质选自糖胺、维生素B3、类视色素、肽、植物甾醇、二烷酰基羟脯氨酸、去氧苯比妥、水杨酸和它们的衍生物、或它们的混合物;和
c)皮肤病学可接受的载体。
2.如权利要求1所述的护肤组合物,所述护肤组合物包含按所述组合物的重量计0.0001%至25%,优选0.001%至10%,更优选0.01%至5%的所述N-酰基氨基酸化合物。
3.如权利要求1或权利要求2所述的护肤组合物,其中所述N-酰基氨基酸化合物选自N-酰基苯基丙氨酸、N-酰基酪氨酸、它们的异构体、它们的盐、或它们的衍生物,优选N-酰基苯基丙氨酸。
4.如权利要求3所述的护肤组合物,其中所述N-酰基苯基丙氨酸包括N-十一碳烯酰基-L-苯基丙氨酸。
5.如前述任一项权利要求所述的护肤组合物,其中所述护肤活性物质包括维生素B3化合物,优选其中所述维生素B3化合物包括烟酰胺。
6.如前述任一项权利要求所述的护肤组合物,所述护肤组合物包含按所述组合物的重量计0.02%至2.5%的N-十一碳烯酰基-L-苯基丙氨酸,和2%至5%的烟酰胺。
7.如前述任一项权利要求所述的护肤组合物,所述护肤组合物还包含按所述组合物的重量计0.001%至10%的附加组分,所述附加组分选自脱屑活性物质、抗痤疮活性物质、皱纹修复活性物质、抗氧化剂、自由基清除剂、螯合剂、类黄酮、抗炎剂、抗蜂窝炎剂、晒黑活性物质、亮肤剂、抗微生物活性物质、抗真菌活性物质、防晒活性物质、调理剂、增稠剂、水溶性维生素、颗粒物质、局部麻醉剂、或它们的组合。
8.如前述任一项权利要求所述的护肤组合物,所述护肤组合物还包含抗坏血酸基葡糖苷。
9.如前述任一项权利要求所述的护肤组合物,其中所述组合物为乳液形式,优选地其中所述乳液选自油包水乳液、水包油乳液、或它们的组合。
10.一种调节哺乳动物角质组织状况的美容方法,所述方法包括将如前述任一项权利要求所述的组合物局部涂敷到需要这种处理的哺乳动物皮肤上的步骤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/627,533 | 2003-07-25 | ||
US10/627,533 US20050019356A1 (en) | 2003-07-25 | 2003-07-25 | Regulation of mammalian keratinous tissue using N-acyl amino acid compositions |
PCT/US2004/022702 WO2005011627A2 (en) | 2003-07-25 | 2004-07-15 | Regulation of mammalian keratinous tissue using n-acyl amino acid compositons |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1822812A true CN1822812A (zh) | 2006-08-23 |
CN1822812B CN1822812B (zh) | 2010-05-26 |
Family
ID=34080666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800198619A Expired - Lifetime CN1822812B (zh) | 2003-07-25 | 2004-07-15 | 一种护肤组合物及其应用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050019356A1 (zh) |
EP (1) | EP1651178A2 (zh) |
JP (1) | JP2006528935A (zh) |
KR (1) | KR100833831B1 (zh) |
CN (1) | CN1822812B (zh) |
AU (1) | AU2004260656A1 (zh) |
BR (1) | BRPI0412756A (zh) |
CA (1) | CA2529632A1 (zh) |
MX (1) | MXPA06000930A (zh) |
WO (1) | WO2005011627A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298449A (zh) * | 2010-11-19 | 2013-09-11 | 宝洁公司 | 用于抑制或降低胰蛋白酶活性的、基于环己-1,2,3,4,5,6-六醇和n-酰基氨基酸化合物的化妆品组合物和方法 |
CN105085611A (zh) * | 2011-11-18 | 2015-11-25 | A&Pep公司 | 具有皮肤美白效果的烟酸-肽和其用途 |
CN107501570A (zh) * | 2017-09-27 | 2017-12-22 | 金华职业技术学院 | 一种金属镉配位聚合物及其制备方法 |
CN115844756A (zh) * | 2022-12-07 | 2023-03-28 | 麦吉丽生物科技有限公司 | 一种具有改善皮肤光泽的组合物、脂质体及其制备方法和应用 |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050249684A1 (en) * | 2004-05-07 | 2005-11-10 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Taurate formulated pigmented cosmetic composition exhibiting radiance with soft focus |
ES2311236T3 (es) * | 2004-10-19 | 2009-02-01 | The Boots Company Plc | Composiciones cosmeticos. |
US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
US7749545B2 (en) | 2005-03-18 | 2010-07-06 | Sakura Properties, Llc | Fucoidan compositions and methods for dietary and nutritional supplements |
US20060210688A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Dehydrated sports drink powder |
US20060210697A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Infant formula composition |
US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
US20060210692A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Baby food composition |
US7776365B2 (en) * | 2005-03-18 | 2010-08-17 | Sakura Properties, Llc | Article with skin protecting and moisturizing compound |
US20060210496A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Compositions for skin protection from ultraviolet damage |
US7666448B2 (en) | 2005-03-18 | 2010-02-23 | Sakura Properties, Llc | Skin cleansing article |
US20060263400A1 (en) * | 2005-05-17 | 2006-11-23 | Bissett Donald L | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
CN103127111B (zh) * | 2005-06-24 | 2016-02-10 | 代表亚利桑那大学的亚利桑那校董会 | 用于治疗头发生长病症比如女性型脱发的方法及可用于此的组合物 |
EP1743624A1 (en) * | 2005-07-12 | 2007-01-17 | Johnson & Johnson Consumer France SAS | Silicone-in-water emulsion compositions containing retinoids |
US9089493B2 (en) * | 2005-09-16 | 2015-07-28 | The Procter & Gamble Company | Skin care composition |
EP1905422A1 (en) * | 2006-09-28 | 2008-04-02 | Johnson & Johnson Consumer France SAS | Stabilized compositons containing retinoids and metal oxide pigments |
FR2908651B1 (fr) * | 2006-11-21 | 2012-06-29 | Oreal | Composition cosmetique comprenant un derive de proline et ou un sel dudit derive |
DE102007005093A1 (de) | 2007-01-25 | 2008-07-31 | Beiersdorf Ag | Kosmetische Zubereitung gegen Hautpigmentierungen |
WO2009003996A1 (en) * | 2007-07-05 | 2009-01-08 | Unilever Plc | Improved cosmetic composition for skin lightening |
FR2935379B1 (fr) * | 2008-09-03 | 2012-08-31 | Seppic Sa | Utilisation de n-acyl aminoacides comme principe actifs cosmetiques et pharmaceutiques, regulateurs de la proportion de keratinocytes basaux de l'epiderme de la peau humaine exprimant la forme nucleaire de la survivine ; compositions |
JP2012509322A (ja) * | 2008-11-24 | 2012-04-19 | ザ プロクター アンド ギャンブル カンパニー | 化粧品組成物 |
US9676696B2 (en) * | 2009-01-29 | 2017-06-13 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
CN102378620A (zh) * | 2009-03-20 | 2012-03-14 | 宝洁公司 | 包含烃蜡和极性油的个人护理组合物 |
CN102573781A (zh) * | 2009-03-20 | 2012-07-11 | 宝洁公司 | 包含油溶性固体防晒剂的个人护理组合物 |
US20100305169A1 (en) * | 2009-03-23 | 2010-12-02 | Larry Rich Robinson | Personal-care composition comprising a cationic active |
WO2010111266A2 (en) | 2009-03-23 | 2010-09-30 | The Procter & Gamble Company | Personal-care composition comprising a cationic active |
KR101443927B1 (ko) | 2009-08-20 | 2014-09-25 | (주)아모레퍼시픽 | 헥사미딘류 및 레티노이드류를 함유하는 피부 개선 조성물 |
WO2011050493A1 (en) * | 2009-10-29 | 2011-05-05 | The Procter & Gamble Company | Transparent cosmetic composition and preparation method thereof |
US9585823B2 (en) | 2010-01-07 | 2017-03-07 | The Gillette Company | Personal care compositions comprising a multi-active system for down regulating cytokines irritation |
US20110177017A1 (en) | 2010-01-15 | 2011-07-21 | Timothy Woodrow Coffindaffer | Non-Aerosol Personal Care Compositions Comprising A Hydrophobically Modified Cationic Polysaccharide |
US20110177018A1 (en) | 2010-01-15 | 2011-07-21 | Paul Martin Lipic | Personal Care Compositions Comprising A Hydrophobically Modified Cationic Polysaccharide |
US9044429B2 (en) | 2010-01-15 | 2015-06-02 | The Gillette Company | Personal care compositions comprising a methyl naphthalenyl ketone or a derivative thereof |
WO2011103146A2 (en) | 2010-02-16 | 2011-08-25 | The Procter & Gamble Company | A post foaming gel composition comprising an anti-irritation agent |
WO2011103173A2 (en) | 2010-02-17 | 2011-08-25 | The Procter & Gamble Company | Non-aerosol personal care compositions comprising an anti-irritation agent |
US20110274627A1 (en) | 2010-05-06 | 2011-11-10 | Ali Abdelaziz Alwattari | Method Of Making An Aerosol Shave Composition Comprising A Hydrophobical Agent Forming At Least One Microdroplet |
US20110272320A1 (en) | 2010-05-06 | 2011-11-10 | Ali Abdelaziz Alwattari | Aerosol Shave Composition Comprising A Hydrophobical Agent Forming At Least One Microdroplet |
KR101275351B1 (ko) * | 2010-06-29 | 2013-06-17 | (주)아모레퍼시픽 | 노화방지용 화장료 조성물 |
US20120035557A1 (en) | 2010-07-16 | 2012-02-09 | Timothy Woodrow Coffindaffer | Personal Care Compositions Comprising A Multi-Active System For Down Regulating Cytokines Irritation |
EP2448548B1 (en) * | 2010-07-22 | 2017-03-01 | The Procter and Gamble Company | Method for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina |
WO2012011908A1 (en) * | 2010-07-22 | 2012-01-26 | The Procter & Gamble Company | Compositions and methods for inhibiting par2 activation of keratinocytes |
ES2610205T3 (es) * | 2010-08-27 | 2017-04-26 | Neopharm Co., Ltd. | Compuesto novedoso que acelera la secreción de péptido antimicrobiano de origen humano, método para preparar el mismo, y composición que tiene el mismo como principio activo |
JP5695388B2 (ja) * | 2010-10-07 | 2015-04-01 | 花王株式会社 | 水中油型乳化組成物 |
US20120087981A1 (en) | 2010-10-11 | 2012-04-12 | Xiandong Wang | Skin Engaging Member Comprising Encapsulated Actives |
FR2967056B1 (fr) * | 2010-11-05 | 2012-11-09 | Oreal | Composition solaire fluide aqueuse a base d'un polymere superabsorbant et d'un copolymere reticule d'acide methacrylique et d'acrylate d'alkyle en c1-c4. |
KR20130090415A (ko) | 2010-11-18 | 2013-08-13 | 더 프록터 앤드 갬블 캄파니 | N-아실 아미노산 화합물 및 헥실데칸올을 기재로 하는 화장 조성물 |
CN103857378B (zh) * | 2011-08-03 | 2016-05-04 | 株式会社资生堂 | 角栓再生抑制剂、角栓再生抑制方法以及角栓再生抑制试剂盒 |
US20130042482A1 (en) | 2011-08-16 | 2013-02-21 | Valerie Jean Bradford | Skin Engaging Member Comprising An Anti-Irritation Agent |
US20130045257A1 (en) | 2011-08-16 | 2013-02-21 | Ali Alwattari | Aerosol shave composition comprising a hydrophobical agent forming at least one microdroplet and an anti-irritation agent |
US20130045248A1 (en) | 2011-08-16 | 2013-02-21 | Timothy Woodrow Coffindaffer | Personal care compositions comprising an anti-irritation agent |
CN104254315B (zh) * | 2012-04-19 | 2017-06-09 | 宝洁公司 | 包含环氧烷衍生物和n‑酰基氨基酸化合物的化妆品组合物 |
US20130280174A1 (en) | 2012-04-20 | 2013-10-24 | The Gillette Company | Personal care composition comprising metathesized unsaturated polyol esters |
JP6009262B2 (ja) * | 2012-07-31 | 2016-10-19 | 花王株式会社 | 乳化型クレンジング化粧料 |
RU2015105518A (ru) | 2012-09-28 | 2016-11-20 | Дзе Жиллетт Компани | Контактирующий с кожей элемент вспомогательного средства для бритья, содержащий, по меньшей мере, одно термоустойчивое вещество, оказывающее сенсорное воздействие |
ES2644137T3 (es) | 2012-09-28 | 2017-11-27 | The Gillette Company | Miembro de acoplamiento con la piel que comprende al menos un agente percibido por los sentidos térmicamente resilente |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
JP6434203B2 (ja) * | 2013-05-14 | 2018-12-05 | 味の素株式会社 | N−アシルヒドロキシ中性アミノ酸またはその塩を含有する組成物 |
US9005674B1 (en) | 2013-07-01 | 2015-04-14 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
US20150272847A1 (en) | 2014-03-26 | 2015-10-01 | The Gillette Company | Skin Engaging Shaving Aid Comprising A Thermally Resilient Sensate And A TRPA1 Receptor Inhibitor |
CN107000234A (zh) | 2014-11-26 | 2017-08-01 | 吉列有限公司 | 包含乙烯乙酸乙烯酯的皮肤接合构件 |
WO2017094852A1 (ja) * | 2015-12-02 | 2017-06-08 | 味の素株式会社 | 外用組成物 |
US11504348B2 (en) * | 2015-12-15 | 2022-11-22 | L'oreal | Iontophoresis method of delivering vitamin C through the skin and iontophoresis device comprising: an electrode assembly including at least one electrode and an aqueous active agent |
US20170334082A1 (en) | 2016-05-18 | 2017-11-23 | The Gillette Company Llc | Skin Engaging Member Comprising Ethylene Vinyl Acetate |
EP3535028A1 (en) | 2016-11-03 | 2019-09-11 | The Gillette Company LLC | Skin engaging member comprising ethylene vinyl acetate |
CN109843385B (zh) | 2016-11-17 | 2022-06-03 | 吉列有限责任公司 | 包含乙烯-乙酸乙烯酯和芳香剂的皮肤接合构件 |
WO2018111952A1 (en) * | 2016-12-13 | 2018-06-21 | The Procter & Gamble Company | Stable personal care compositions containing a retinoid |
JP6943024B2 (ja) * | 2017-06-02 | 2021-09-29 | 味の素株式会社 | 外用組成物 |
WO2018220916A1 (ja) * | 2017-06-02 | 2018-12-06 | 味の素株式会社 | 外用組成物 |
JP7102687B2 (ja) * | 2017-06-02 | 2022-07-20 | 味の素株式会社 | 外用組成物 |
WO2019094913A2 (en) | 2017-11-13 | 2019-05-16 | The Procter & Gamble Company | Personal care composition |
EP4230265A4 (en) * | 2020-10-30 | 2024-05-08 | Nissan Chemical Corporation | COMPOSITION CONTAINING A LIPID PEPTIDE AND A SUCCAROSE ESTER |
US20230320949A1 (en) | 2022-04-12 | 2023-10-12 | The Procter & Gamble Company | Compositions Having Capsules |
WO2024178013A1 (en) | 2023-02-21 | 2024-08-29 | B.A.I. Laboratories, Llc | Macromolecular chemical uv filters |
WO2024178023A1 (en) | 2023-02-21 | 2024-08-29 | B.A.I. Laboratories, Llc | Macromolecular chemical uv filters |
WO2024178019A1 (en) | 2023-02-21 | 2024-08-29 | B.A.I. Laboratories, Llc | Macromolecular chemical uv filters |
WO2024178014A1 (en) | 2023-02-21 | 2024-08-29 | B.A.I. Laboratories, Llc | Macromolecular chemical uv filters |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2097256B (en) * | 1981-04-02 | 1985-05-30 | Morelle Jean V | Compositions containing n-butyryl alphaaminoacids |
FR2564016B1 (fr) * | 1984-05-11 | 1989-02-17 | Commissariat Energie Atomique | Procede de recalage de la trajectoire d'un organe et dispositif pour la mise en oeuvre de ce procede |
AU2971689A (en) * | 1988-02-11 | 1989-08-17 | Estee Lauder Inc. | Tanning compositions and their use |
US5451405A (en) * | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
JPH07331281A (ja) * | 1994-06-07 | 1995-12-19 | Ajinomoto Co Inc | 洗浄剤組成物 |
US5833998A (en) * | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
US5939082A (en) * | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
US6238678B1 (en) * | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
JPH09175926A (ja) * | 1995-12-25 | 1997-07-08 | Kanebo Ltd | 皮膚外用剤組成物 |
US5912014A (en) * | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
FR2749511B1 (fr) * | 1996-06-07 | 1998-08-28 | Roc Sa | Methode cosmetique de traitement et de prevention des signes du vieillissement de la peau |
JPH10130128A (ja) * | 1996-10-29 | 1998-05-19 | Kashima Sekiyu Kk | 化粧料 |
FR2775595B1 (fr) * | 1998-03-09 | 2000-05-05 | Seppic Sa | Composition synergique comprenant un compose a structure lipoaminoacide et un extrait de menuphar |
US6703031B1 (en) * | 1998-10-09 | 2004-03-09 | Ajinomoto Co., Inc. | Cysteine derivatives |
JP2000136124A (ja) * | 1998-10-30 | 2000-05-16 | Pias Arise Kk | 皮膚外用剤 |
FR2787323B1 (fr) * | 1998-12-22 | 2003-02-14 | Seppic Sa | Utilisation de composes n-acyles d'aminoacides comme agent de texture |
US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
JP4001310B2 (ja) * | 1999-09-30 | 2007-10-31 | 株式会社資生堂 | 脂質複合体及びこれを含有する外用組成物 |
CA2393732C (en) * | 1999-12-17 | 2005-12-20 | The Procter & Gamble Company | Compositions for efficient release of active ingredients |
FR2808441B1 (fr) * | 2000-05-04 | 2004-06-18 | Oreal | Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau |
JP4841075B2 (ja) * | 2000-09-22 | 2011-12-21 | 旭化成ケミカルズ株式会社 | 美白化粧料 |
WO2002062312A1 (en) * | 2001-02-08 | 2002-08-15 | The Procter & Gamble Company | Mask composition |
ATE369116T1 (de) * | 2001-02-16 | 2007-08-15 | Oreal | Kosmetische verwendung eines vinylpyrrolidon/alken-copolymeres, um das aussehen der haut und/oder des semischleimhäute zu verändern |
FR2820977A1 (fr) * | 2001-02-22 | 2002-08-23 | Oreal | Composition cosmetique matifiante a base de dispersion aqueuse de polytetrafluoroethylene |
JP2002284662A (ja) * | 2001-03-27 | 2002-10-03 | Kanebo Ltd | 皮膚外用剤組成物 |
ES2320103T3 (es) * | 2001-06-26 | 2009-05-19 | L'oreal | Composiciones que comprenden un compuesto de baja solubilidad y un derivado lipofilo de acido aminado, utilizaciones y procedimientos correspondientes. |
JP2003095853A (ja) * | 2001-09-27 | 2003-04-03 | Kanebo Ltd | 皮膚外用剤 |
JP2003104864A (ja) * | 2001-09-28 | 2003-04-09 | Kose Corp | 美白化粧料 |
FR2835252B1 (fr) * | 2002-01-25 | 2005-08-05 | Seppic Sa | Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau |
-
2003
- 2003-07-25 US US10/627,533 patent/US20050019356A1/en not_active Abandoned
-
2004
- 2004-07-15 AU AU2004260656A patent/AU2004260656A1/en not_active Abandoned
- 2004-07-15 CA CA002529632A patent/CA2529632A1/en not_active Abandoned
- 2004-07-15 EP EP04778280A patent/EP1651178A2/en not_active Withdrawn
- 2004-07-15 JP JP2006521877A patent/JP2006528935A/ja active Pending
- 2004-07-15 KR KR1020067000751A patent/KR100833831B1/ko active IP Right Grant
- 2004-07-15 WO PCT/US2004/022702 patent/WO2005011627A2/en active Application Filing
- 2004-07-15 CN CN2004800198619A patent/CN1822812B/zh not_active Expired - Lifetime
- 2004-07-15 BR BRPI0412756-0A patent/BRPI0412756A/pt not_active Application Discontinuation
- 2004-07-15 MX MXPA06000930A patent/MXPA06000930A/es unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103298449A (zh) * | 2010-11-19 | 2013-09-11 | 宝洁公司 | 用于抑制或降低胰蛋白酶活性的、基于环己-1,2,3,4,5,6-六醇和n-酰基氨基酸化合物的化妆品组合物和方法 |
CN105085611A (zh) * | 2011-11-18 | 2015-11-25 | A&Pep公司 | 具有皮肤美白效果的烟酸-肽和其用途 |
CN105085611B (zh) * | 2011-11-18 | 2019-07-19 | A&Pep公司 | 具有皮肤美白效果的烟酸-肽和其用途 |
CN107501570A (zh) * | 2017-09-27 | 2017-12-22 | 金华职业技术学院 | 一种金属镉配位聚合物及其制备方法 |
CN107501570B (zh) * | 2017-09-27 | 2020-09-29 | 金华职业技术学院 | 一种金属镉配位聚合物及其制备方法 |
CN115844756A (zh) * | 2022-12-07 | 2023-03-28 | 麦吉丽生物科技有限公司 | 一种具有改善皮肤光泽的组合物、脂质体及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
MXPA06000930A (es) | 2006-03-30 |
CA2529632A1 (en) | 2005-02-10 |
KR20060037341A (ko) | 2006-05-03 |
WO2005011627A2 (en) | 2005-02-10 |
AU2004260656A1 (en) | 2005-02-10 |
CN1822812B (zh) | 2010-05-26 |
KR100833831B1 (ko) | 2008-06-02 |
EP1651178A2 (en) | 2006-05-03 |
US20050019356A1 (en) | 2005-01-27 |
JP2006528935A (ja) | 2006-12-28 |
BRPI0412756A (pt) | 2006-09-26 |
WO2005011627A3 (en) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1822812A (zh) | 使用n-酰基氨基酸组合物调节哺乳动物的角质组织 | |
CN1774231A (zh) | 调节哺乳动物角质组织的组合物和方法 | |
CN1870968A (zh) | 包含脱氢乙酸和护肤活性物质的护肤组合物 | |
CN1275702C (zh) | 护肤套件 | |
CN1256936C (zh) | 包含糖胺的护肤组合物 | |
CN1756528A (zh) | 使用去氧苯比妥组合物对哺乳动物角质组织的调节 | |
CN1198580C (zh) | 包含聚硅氧烷弹性体的护肤组合物 | |
CN1697646A (zh) | 维生素b6组合物的局部应用 | |
CN1313073C (zh) | 包含水解蛋白质的局部用皮肤和/或毛发组合物 | |
CN1177580C (zh) | 植物甾醇组合物及其应用 | |
US7175836B1 (en) | Oil continuous phase cosmetic emulsions with conjugated linoleic acid | |
US20070297997A1 (en) | Personal care composition | |
MX2008014662A (es) | Composiciones de emulsiones de agua en aceite que contienen activos protectores solares y elastomeros de siloxano. | |
CN1347308A (zh) | 包含护肤活性物组合的护肤组合物 | |
CN1347310A (zh) | 包含护肤活性物组合的护肤组合物 | |
CN1254230C (zh) | 增强油溶性护肤活性剂的输送的方法 | |
US20070134173A1 (en) | Personal care compositions | |
CN101443081A (zh) | 包含防晒活性物质和硅氧烷弹性体的油包水乳液组合物 | |
CN1870965A (zh) | 提供共混组合物的方法 | |
CN1929759A (zh) | 角质组织的处理 | |
CN1198579C (zh) | 美容方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20100526 |